

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/074843 A1

(51) International Patent Classification⁷: **G01N 33/88**,
C12Q 1/68

(21) International Application Number:
PCT/EP2004/001199

(22) International Filing Date: 10 February 2004 (10.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03003250.2 24 February 2003 (24.02.2003) EP

(71) Applicant (for all designated States except US): **BAYER
HEALTHCARE AG** [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOLZ, Stefan**
[DE/DE]; Bückmannsmühle 46, 45326 Essen (DE).
BRÜGGEMEIER, Ulf [DE/DE]; Leysiefen 20, 42799
Leichlingen (DE). **GEERTS, Andreas** [DE/DE]; Schuck-
ertstr. 29, 42113 Wuppertal (DE).

(74) Common Representative: **BAYER HEALTHCARE
AG**; Law & Patents, Patents and Licensing, 51368 Lev-
erkusen (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH G-PROTEIN COUPLED RECEPTOR PROSTAGLANDIN E2 EP1 (PROSTAGLANDIN E2 EP1)

(57) Abstract: The invention provides a human prostaglandin E2 EP1 which is associated with the cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of prostaglandin E2 EP1 as well as pharmaceutical compositions comprising such compounds.



WO 2004/074843 A1

- 1 -

**Diagnostics and Therapeutics for Diseases Associated with G-Protein
Coupled Receptor Prostaglandin E2 EP1 (Prostaglandin E2 EP1)**

5 **Technical field of the invention**

The present invention is in the field of molecular biology, more particularly, the present invention relates to nucleic acid sequences and amino acid sequences of a human prostaglandin E2 EP1 and its regulation for the treatment of cardiovascular
10 diseases, respiratory diseases, hematological diseases, urological diseases, gastro-intestinal diseases, endocrinological diseases and metabolic diseases in mammals.

Background of the invention

15 **G-Protein Coupled Receptors**

prostaglandin E2 EP1 is a seven transmembrane G protein coupled receptor (GPCR) [[Funk et al., (1993)]; [Coleman et al. (1994)], [Sales et al. (2001)], WO02081745, WO02061087, US 6440680, US 5985597]. Many medically significant biological
20 processes are mediated by signal transduction pathways that involve G-proteins [Lefkowitz, (1991)]. The family of G-protein coupled receptors (GPCRs) includes receptors for hormones, neurotransmitters, growth factors, and viruses. Specific examples of GPCRs include receptors for such diverse agents as dopamine, calcitonine, adrenergic hormones, endotheline, cAMP, adenosine, acetylcholine,
25 serotonin, histamine, thrombin, kinine, follicle stimulating hormone, opsins, endothelial differentiation gene-1, rhodopsins, odorants, cytomegalovirus, G-proteins themselves, effector proteins such as phospholipase C, adenylyl cyclase, and phosphodiesterase, and actuator proteins such as protein kinase A and protein kinase C.

30

GPCRs possess seven conserved membrane-spanning domains connecting at least eight divergent hydrophilic loops. GPCRs, also known as seven transmembrane,

- 2 -

7TM; receptors, have been characterized as including these seven conserved hydrophobic stretches of about 20 to 30 amino acids, connecting at least eight divergent hydrophilic loops. Most GPCRs have single conserved cysteine residues in each of the first two extracellular loops, which form disulfide bonds that are believed to stabilize functional protein structure. The seven transmembrane regions are designated as TM1, TM2, TM3, TM4, TM5, TM6, and TM7. TM3 is being implicated with signal transduction. Phosphorylation and lipidation (palmitoylation or farnesylation) of cysteine residues can influence signal transduction of some GPCRs. Most GPCRs contain potential phosphorylation sites within the third cytoplasmic loop and/or the carboxy terminus. For several GPCRs, such as the beta-adrenergic receptor, phosphorylation by protein kinase A and/or specific receptor kinases mediates receptor desensitization.

For some receptors, the ligand binding sites of GPCRs are believed to comprise hydrophilic sockets formed by several GPCR transmembrane domains. The hydrophilic sockets are surrounded by hydrophobic residues of the GPCRs. The hydrophilic side of each GPCR transmembrane helix is postulated to face inward and form a polar ligand binding site. TM3 is being implicated with several GPCRs as having a ligand binding site, such as the TM3 aspartate residue. TM5 serines, a TM6 asparagine, and TM6 or TM7 phenylalanines or tyrosines also are implicated in ligand binding.

GPCRs are coupled inside the cell by heterotrimeric G-proteins to various intracellular enzymes, ion channels, and transporters. Different G-protein alpha-subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of GPCRs is an important mechanism for the regulation of some GPCRs. For example, in one form of signal transduction, the effect of hormone binding is the activation of the enzyme, adenylate cyclase, inside the cell. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP. GTP also influences hormone binding. A G-protein connects the hormone receptor to adenylate cyclase. G-protein exchanges

- 3 -

GTP for bound GDP when activated by a hormone receptor. The GTP-carrying form then binds to activated adenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself, returns the G-protein to its basal, inactive form. Thus, the G-protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a clock that controls the duration of the signal.

Over the past 15 years, nearly 350 therapeutic agents targeting 7TM receptors have been successfully introduced into the market. This indicates that these receptors have an established, proven history as therapeutic targets. Clearly, there is a need for identification and characterization of further receptors which can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, cancers, allergies including asthma, cardiovascular diseases including acute heart failure, hypotension, hypertension, angina pectoris, myocardial infarction, hematological diseases, genito-urinary diseases including urinary incontinence and benign prostate hyperplasia, osteoporosis, and peripheral and central nervous system disorders including pain, Alzheimer's disease and Parkinson's disease.

20 TaqMan-Technology / expression profiling

TaqMan is a recently developed technique, in which the release of a fluorescent reporter dye from a hybridisation probe in real-time during a polymerase chain reaction (PCR) is proportional to the accumulation of the PCR product. Quantification is based on the early, linear part of the reaction, and by determining the threshold cycle (CT), at which fluorescence above background is first detected.

Gene expression technologies may be useful in several areas of drug discovery and development, such as target identification, lead optimization, and identification of mechanisms of action. The TaqMan technology can be used to compare differences between expression profiles of normal tissue and diseased tissue. Expression

- 4 -

profiling has been used in identifying genes, which are up- or downregulated in a variety of diseases. An interesting application of expression profiling is temporal monitoring of changes in gene expression during disease progression and drug treatment or in patients versus healthy individuals. The premise in this approach is that changes in pattern of gene expression in response to physiological or environmental stimuli (e.g., drugs) may serve as indirect clues about disease-causing genes or drug targets. Moreover, the effects of drugs with established efficacy on global gene expression patterns may provide a guidepost, or a genetic signature, against which a new drug candidate can be compared.

prostaglandin E2 EP1

The nucleotide sequence of prostaglandin E2 EP1 is accessible in public databases by the accession number NM_000955 and is given in SEQ ID NO: 1. The amino acid sequence of prostaglandin E2 EP1 is depicted in SEQ ID NO: 2

Prostaglandin E2 EP1 was identified as a receptor for iloprost and PGE2 (for example) [Funk et al., (1993)].

Prostanoid receptors of the EP1, EP2, EP3, and EP4 types cloned in the mouse and/or human were reviewed by Coleman et al. [Coleman et al. (1994)]. Prostaglandin E2 (PGE2), one of various oxygenated metabolites of arachidonic acid, produces a broad range of biologic actions in diverse tissues. Not only are PGE2 and thromboxane A2 structurally related, but their receptors are also homologous. Epithelial tumors may be regulated by cyclooxygenase (COX) enzyme products. To determine if COX2 expression and PGE2 synthesis are upregulated in cervical cancers, [Sales et al. (2001)] used real-time quantitative PCR and Western blot analysis to confirm COX2 RNA and protein expression in squamous cell carcinomas and adenocarcinomas.

- 5 -

The receptor prostaglandin E2 EP1 is also described in patents WO02081745, WO02061087, US 6440680 and US 5985597 .

Summary of the invention

5

The invention relates to novel disease associations of prostaglandin E2 EP1 polypeptides and polynucleotides. The invention also relates to novel methods of screening for therapeutic agents for the treatment of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal. The invention also relates to pharmaceutical compositions for the treatment of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising a prostaglandin E2 EP1 polypeptide, a prostaglandin E2 EP1 polynucleotide, or regulators of prostaglandin E2 EP1 or modulators of prostaglandin E2 EP1 activity. The invention further comprises methods of diagnosing cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal.

20

Brief Description of the Drawings

Fig. 1 shows the nucleotide sequence of a prostaglandin E2 EP1 receptor polynucleotide (SEQ ID NO: 1).

25 Fig. 2 shows the amino acid sequence of a prostaglandin E2 EP1 receptor polypeptide (SEQ ID NO: 2).

Fig. 3 shows the nucleotide sequence of a primer useful for the invention (SEQ ID NO: 3).

30 Fig. 4 shows the nucleotide sequence of a primer useful for the invention (SEQ ID NO: 4).

Fig. 5 shows a nucleotide sequence useful as a probe to detect proteins of the invention (SEQ ID NO: 5).

5 Detailed description of the invention

Definition of terms

10 An "oligonucleotide" is a stretch of nucleotide residues which has a sufficient number of bases to be used as an oligomer, amplimer or probe in a polymerase chain reaction (PCR). Oligonucleotides are prepared from genomic or cDNA sequence and are used to amplify, reveal, or confirm the presence of a similar DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 35 nucleotides,
15 preferably about 25 nucleotides.

"Probes" may be derived from naturally occurring or recombinant single- or double-stranded nucleic acids or may be chemically synthesized. They are useful in detecting the presence of identical or similar sequences. Such probes may be labeled
20 with reporter molecules using nick translation, Klenow fill-in reaction, PCR or other methods well known in the art. Nucleic acid probes may be used in southern, northern or in situ hybridizations to determine whether DNA or RNA encoding a certain protein is present in a cell type, tissue, or organ.

25 A "fragment of a polynucleotide" is a nucleic acid that comprises all or any part of a given nucleotide molecule, the fragment having fewer nucleotides than about 6 kb, preferably fewer than about 1 kb.

30 "Reporter molecules" are radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents which associate with a particular nucleotide or amino acid

- 7 -

sequence, thereby establishing the presence of a certain sequence, or allowing for the quantification of a certain sequence.

5 “Chimeric” molecules may be constructed by introducing all or part of the nucleotide sequence of this invention into a vector containing additional nucleic acid sequence which might be expected to change any one or several of the following prostaglandin E2 EP1 characteristics: cellular location, distribution, ligand-binding affinities, interchain affinities, degradation/turnover rate, signaling, etc.

10 “Active”, with respect to a prostaglandin E2 EP1 polypeptide, refers to those forms, fragments, or domains of a prostaglandin E2 EP1 polypeptide which retain the biological and/or antigenic activity of a prostaglandin E2 EP1 polypeptide.

15 “Naturally occurring prostaglandin E2 EP1 polypeptide” refers to a polypeptide produced by cells which have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including but not limited to acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

20 “Derivative” refers to polypeptides which have been chemically modified by techniques such as ubiquitination, labeling (see above), pegylation (derivatization with polyethylene glycol), and chemical insertion or substitution of amino acids such as ornithine which do not normally occur in human proteins.

25 “Conservative amino acid substitutions” result from replacing one amino acid with another having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

30 “Insertions” or “deletions” are typically in the range of about 1 to 5 amino acids. The variation allowed may be experimentally determined by producing the peptide

- 8 -

synthetically while systematically making insertions, deletions, or substitutions of nucleotides in the sequence using recombinant DNA techniques.

5 A "signal sequence" or "leader sequence" can be used, when desired, to direct the polypeptide through a membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous sources by recombinant DNA techniques.

10 An "oligopeptide" is a short stretch of amino acid residues and may be expressed from an oligonucleotide. Oligopeptides comprise a stretch of amino acid residues of at least 3, 5, 10 amino acids and at most 10, 15, 25 amino acids, typically of at least 9 to 13 amino acids, and of sufficient length to display biological and/or antigenic activity.

15 "Inhibitor" is any substance which retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.

20 "Standard expression" is a quantitative or qualitative measurement for comparison. It is based on a statistically appropriate number of normal samples and is created to use as a basis of comparison when performing diagnostic assays, running clinical trials, or following patient treatment profiles.

25 "Animal" as used herein may be defined to include human, domestic (e.g., cats, dogs, etc.), agricultural (e.g., cows, horses, sheep, etc.) or test species (e.g., mouse, rat, rabbit, etc.).

A "prostaglandin E2 EP1 polynucleotide", within the meaning of the invention, shall be understood as being a nucleic acid molecule selected from a group consisting of

- 9 -

- 5
- (i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2,
 - (ii) nucleic acid molecules comprising the sequence of SEQ ID NO: 1,
 - (iii) nucleic acid molecules having the sequence of SEQ ID NO: 1,
 - (iv) nucleic acid molecules the complementary strand of which hybridizes under stringent conditions to a nucleic acid molecule of (i), (ii), or (iii); and
 - 10 (v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid molecule of (iii) due to the degeneracy of the genetic code;

15 wherein the polypeptide encoded by said nucleic acid molecule has prostaglandin E2 EP1 activity.

A "prostaglandin E2 EP1 polypeptide", within the meaning of the invention, shall be understood as being a polypeptide selected from a group consisting of

- 20
- (i) polypeptides having the sequence of SEQ ID NO: 2,
 - (ii) polypeptides comprising the sequence of SEQ ID NO: 2,
 - (iii) polypeptides encoded by prostaglandin E2 EP1 polynucleotides; and
 - 25 (iv) polypeptides which show at least 99%, 98%, 95%, 90%, or 80% homology with a polypeptide of (i), (ii), or (iii);

30 wherein said polypeptide has prostaglandin E2 EP1 activity.

- 10 -

The nucleotide sequences encoding a prostaglandin E2 EP1 (or their complement) have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use in the construction of oligomers for PCR, use for chromosome and gene mapping, use in the recombinant production of prostaglandin E2 EP1, and use in generation of antisense DNA or RNA, their chemical analogs and the like. Uses of nucleotides encoding a prostaglandin E2 EP1 disclosed herein are exemplary of known techniques and are not intended to limit their use in any technique known to a person of ordinary skill in the art. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of prostaglandin E2 EP1 - encoding nucleotide sequences may be produced. Some of these will only bear minimal homology to the nucleotide sequence of the known and naturally occurring prostaglandin E2 EP1. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring prostaglandin E2 EP1, and all such variations are to be considered as being specifically disclosed.

Although the nucleotide sequences which encode a prostaglandin E2 EP1, its derivatives or its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring prostaglandin E2 EP1 polynucleotide under stringent conditions, it may be advantageous to produce nucleotide sequences encoding prostaglandin E2 EP1 polypeptides or its derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic

- 11 -

expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding a prostaglandin E2 EP1 polypeptide and/or its derivatives without altering the encoded amino acid sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

Nucleotide sequences encoding a prostaglandin E2 EP1 polypeptide may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques. Useful nucleotide sequences for joining to prostaglandin E2 EP1 polynucleotides include an assortment of cloning vectors such as plasmids, cosmids, lambda phage derivatives, phagemids, and the like. Vectors of interest include expression vectors, replication vectors, probe generation vectors, sequencing vectors, etc. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for one or more host cell systems.

Another aspect of the subject invention is to provide for prostaglandin E2 EP1-specific hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding prostaglandin E2 EP1. Such probes may also be used for the detection of similar GPCR encoding sequences and should preferably show at least 40% nucleotide identity to prostaglandin E2 EP1 polynucleotides. The hybridization probes of the subject invention may be derived from the nucleotide sequence presented as SEQ ID NO: 1 or from genomic sequences including promoter, enhancers or introns of the native gene. Hybridization probes may be labelled by a variety of reporter molecules using techniques well known in the art.

It will be recognized that many deletional or mutational analogs of prostaglandin E2 EP1 polynucleotides will be effective hybridization probes for prostaglandin E2 EP1 polynucleotides. Accordingly, the invention relates to nucleic acid sequences that

- 12 -

hybridize with such prostaglandin E2 EP1 encoding nucleic acid sequences under stringent conditions.

“Stringent conditions” refers to conditions that allow for the hybridization of substantially related nucleic acid sequences. For instance, such conditions will generally allow hybridization of sequence with at least about 85% sequence identity, preferably with at least about 90% sequence identity, more preferably with at least about 95% sequence identity. Hybridization conditions and probes can be adjusted in well-characterized ways to achieve selective hybridization of human-derived probes. Stringent conditions, within the meaning of the invention are 65°C in a buffer containing 1 mM EDTA, 0.5 M NaHPO₄ (pH 7.2), 7 % (w/v) SDS.

Nucleic acid molecules that will hybridize to prostaglandin E2 EP1 polynucleotides under stringent conditions can be identified functionally. Without limitation, examples of the uses for hybridization probes include: histochemical uses such as identifying tissues that express prostaglandin E2 EP1; measuring mRNA levels, for instance to identify a sample's tissue type or to identify cells that express abnormal levels of prostaglandin E2 EP1; and detecting polymorphisms of prostaglandin E2 EP1.

PCR provides additional uses for oligonucleotides based upon the nucleotide sequence which encodes prostaglandin E2 EP1. Such probes used in PCR may be of recombinant origin, chemically synthesized, or a mixture of both. Oligomers may comprise discrete nucleotide sequences employed under optimized conditions for identification of prostaglandin E2 EP1 in specific tissues or diagnostic use. The same two oligomers, a nested set of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for identification of closely related DNAs or RNAs.

Rules for designing polymerase chain reaction (PCR) primers are now established, as reviewed by PCR Protocols. Degenerate primers, i.e., preparations of primers that

- 13 -

are heterogeneous at given sequence locations, can be designed to amplify nucleic acid sequences that are highly homologous to, but not identical with prostaglandin E2 EP1. Strategies are now available that allow for only one of the primers to be required to specifically hybridize with a known sequence. For example, appropriate
5 nucleic acid primers can be ligated to the nucleic acid sought to be amplified to provide the hybridization partner for one of the primers. In this way, only one of the primers need be based on the sequence of the nucleic acid sought to be amplified.

PCR methods for amplifying nucleic acid will utilize at least two primers. One of
10 these primers will be capable of hybridizing to a first strand of the nucleic acid to be amplified and of priming enzyme-driven nucleic acid synthesis in a first direction. The other will be capable of hybridizing the reciprocal sequence of the first strand (if the sequence to be amplified is single stranded, this sequence will initially be hypothetical, but will be synthesized in the first amplification cycle) and of priming
15 nucleic acid synthesis from that strand in the direction opposite the first direction and towards the site of hybridization for the first primer. Conditions for conducting such amplifications, particularly under preferred stringent hybridization conditions, are well known.

20 Other means of producing specific hybridization probes for prostaglandin E2 EP1 include the cloning of nucleic acid sequences encoding prostaglandin E2 EP1 or prostaglandin E2 EP1 derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA
25 polymerase as T7 or SP6 RNA polymerase and the appropriate reporter molecules.

It is possible to produce a DNA sequence, or portions thereof, entirely by synthetic chemistry. After synthesis, the nucleic acid sequence can be inserted into any of the many available DNA vectors and their respective host cells using techniques which
30 are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into the nucleotide sequence. Alternately, a portion of sequence in which a

- 14 -

mutation is desired can be synthesized and recombined with longer portion of an existing genomic or recombinant sequence.

5 prostaglandin E2 EP1 polynucleotides may be used to produce a purified oligo-or polypeptide using well known methods of recombinant DNA technology. The oligopeptide may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from the same species from which the nucleotide sequence was derived or from a different species. Advantages of producing an oligonucleotide by recombinant DNA technology include obtaining adequate
10 amounts of the protein for purification and the availability of simplified purification procedures.

Quantitative determinations of nucleic acids

15 An important step in the molecular genetic analysis of human disease is often the enumeration of the copy number of a nucleic acid or the relative expression of a gene in particular tissues.

Several different approaches are currently available to make quantitative deter-
20 minations of nucleic acids. Chromosome-based techniques, such as comparative genomic hybridization (CGH) and fluorescent in situ hybridization (FISH) facilitate efforts to cytogenetically localize genomic regions that are altered in tumor cells. Regions of genomic alteration can be narrowed further using loss of heterozygosity analysis (LOH), in which disease DNA is analyzed and compared with normal DNA
25 for the loss of a heterozygous polymorphic marker. The first experiments used restriction fragment length polymorphisms (RFLPs) [Johnson, (1989)], or hyper-variable minisatellite DNA [Barnes, 2000]. In recent years LOH has been performed primarily using PCR amplification of microsatellite markers and electrophoresis of the radio labelled [Jeffreys, (1985)] or fluorescently labelled PCR products [Weber,
30 (1990)] and compared between paired normal and disease DNAs.

A number of other methods have also been developed to quantify nucleic acids [Gergen, (1992)]. More recently, PCR and RT-PCR methods have been developed which are capable of measuring the amount of a nucleic acid in a sample. One approach, for example, measures PCR product quantity in the log phase of the reaction before the formation of reaction products plateaus [Thomas, (1980)].

A gene sequence contained in all samples at relatively constant quantity is typically utilized for sample amplification efficiency normalization. This approach, however, suffers from several drawbacks. The method requires that each sample has equal input amounts of the nucleic acid and that the amplification efficiency between samples is identical until the time of analysis. Furthermore, it is difficult using the conventional methods of PCR quantitation such as gel electrophoresis or plate capture hybridization to determine that all samples are in fact analyzed during the log phase of the reaction as required by the method.

Another method called quantitative competitive (QC)-PCR, as the name implies, relies on the inclusion of an internal control competitor in each reaction [Piatak, (1993), BioTechniques]. The efficiency of each reaction is normalized to the internal competitor. A known amount of internal competitor is typically added to each sample. The unknown target PCR product is compared with the known competitor PCR product to obtain relative quantitation. A difficulty with this general approach lies in developing an internal control that amplifies with the same efficiency than the target molecule.

5' Fluorogenic Nuclease Assays

Fluorogenic nuclease assays are a real time quantitation method that uses a probe to monitor formation of amplification product. The basis for this method of monitoring the formation of amplification product is to measure continuously PCR product accumulation using a dual-labelled fluorogenic oligonucleotide probe, an approach

- 16 -

frequently referred to in the literature simply as the "TaqMan method" [Piatak, (1993), Science; Heid, (1996); Gibson, (1996); Holland, (1991)].

The probe used in such assays is typically a short (about 20-25 bases) oligo-nucleotide that is labeled with two different fluorescent dyes. The 5' terminus of the probe is attached to a reporter dye and the 3' terminus is attached to a quenching dye, although the dyes could be attached at other locations on the probe as well. The probe is designed to have at least substantial sequence complementarity with the probe binding site. Upstream and downstream PCR primers which bind to flanking regions of the locus are added to the reaction mixture. When the probe is intact, energy transfer between the two fluorophors occurs and the quencher quenches emission from the reporter. During the extension phase of PCR, the probe is cleaved by the 5' nuclease activity of a nucleic acid polymerase such as Taq polymerase, thereby releasing the reporter from the oligonucleotide-quencher and resulting in an increase of reporter emission intensity which can be measured by an appropriate detector.

One detector which is specifically adapted for measuring fluorescence emissions such as those created during a fluorogenic assay is the ABI 7700 or 4700 HT manufactured by Applied Biosystems, Inc. in Foster City, Calif. The ABI 7700 uses fiber optics connected with each well in a 96-or 384 well PCR tube arrangement. The instrument includes a laser for exciting the labels and is capable of measuring the fluorescence spectra intensity from each tube with continuous monitoring during PCR amplification. Each tube is re-examined every 8.5 seconds.

Computer software provided with the instrument is capable of recording the fluorescence intensity of reporter and quencher over the course of the amplification. The recorded values will then be used to calculate the increase in normalized reporter emission intensity on a continuous basis. The increase in emission intensity is plotted versus time, i.e., the number of amplification cycles, to produce a continuous measure of amplification. To quantify the locus in each amplification reaction, the

- 17 -

amplification plot is examined at a point during the log phase of product accumulation. This is accomplished by assigning a fluorescence threshold intensity above background and determining the point at which each amplification plot crosses the threshold (defined as the threshold-cycle number or Ct). Differences in threshold
5 cycle number are used to quantify the relative amount of PCR target contained within each tube. Assuming that each reaction functions at 100% PCR efficiency, a difference of one Ct represents a two-fold difference in the amount of starting template. The fluorescence value can be used in conjunction with a standard curve to determine the amount of amplification product present.

10

Non-Probe-Based Detection Methods

A variety of options are available for measuring the amplification products as they are formed. One method utilizes labels, such as dyes, which only bind to double
15 stranded DNA. In this type of approach, amplification product (which is double stranded) binds dye molecules in solution to form a complex. With the appropriate dyes, it is possible to distinguish between dye molecules free in solution and dye molecules bound to amplification product. For example, certain dyes fluoresce only when bound to amplification product. Examples of dyes which can be used in
20 methods of this general type include, but are not limited to, Syber Green.TM. and Pico Green from Molecular Probes, Inc. of Eugene, Oreg., ethidium bromide, propidium iodide, chromomycin, acridine orange, Hoechst 33258, Toto-1, Yoyo-1, DAPI (4',6-diamidino-2-phenylindole hydrochloride).

25 Another real time detection technique measures alteration in energy fluorescence energy transfer between fluorophors conjugated with PCR primers [Livak, (1995)].

Probe-Based Detection Methods

30 These detection methods involve some alteration to the structure or conformation of a probe hybridized to the locus between the amplification primer pair. In some

- 18 -

instances, the alteration is caused by the template-dependent extension catalyzed by a nucleic acid polymerase during the amplification process. The alteration generates a detectable signal which is an indirect measure of the amount of amplification product formed.

5

For example, some methods involve the degradation or digestion of the probe during the extension reaction. These methods are a consequence of the 5'-3' nuclease activity associated with some nucleic acid polymerases. Polymerases having this activity cleave mononucleotides or small oligonucleotides from an oligonucleotide probe annealed to its complementary sequence located within the locus.

10

The 3' end of the upstream primer provides the initial binding site for the nucleic acid polymerase. As the polymerase catalyzes extension of the upstream primer and encounters the bound probe, the nucleic acid polymerase displaces a portion of the 5' end of the probe and through its nuclease activity cleaves mononucleotides or oligonucleotides from the probe.

15

The upstream primer and the probe can be designed such that they anneal to the complementary strand in close proximity to one another. In fact, the 3' end of the upstream primer and the 5' end of the probe may abut one another. In this situation, extension of the upstream primer is not necessary in order for the nucleic acid polymerase to begin cleaving the probe. In the case in which intervening nucleotides separate the upstream primer and the probe, extension of the primer is necessary before the nucleic acid polymerase encounters the 5' end of the probe. Once contact occurs and polymerization continues, the 5'-3' exonuclease activity of the nucleic acid polymerase begins cleaving mononucleotides or oligonucleotides from the 5' end of the probe. Digestion of the probe continues until the remaining portion of the probe dissociates from the complementary strand.

20

25

30

In solution, the two end sections can hybridize with each other to form a hairpin loop. In this conformation, the reporter and quencher dye are in sufficiently close

- 19 -

proximity that fluorescence from the reporter dye is effectively quenched by the quencher dye. Hybridized probe, in contrast, results in a linearized conformation in which the extent of quenching is decreased. Thus, by monitoring emission changes for the two dyes, it is possible to indirectly monitor the formation of amplification product.

Probes

The labeled probe is selected so that its sequence is substantially complementary to a segment of the test locus or a reference locus. As indicated above, the nucleic acid site to which the probe binds should be located between the primer binding sites for the upstream and downstream amplification primers.

Primers

The primers used in the amplification are selected so as to be capable of hybridizing to sequences at flanking regions of the locus being amplified. The primers are chosen to have at least substantial complementarity with the different strands of the nucleic acid being amplified. When a probe is utilized to detect the formation of amplification products, the primers are selected in such that they flank the probe, i.e. are located upstream and downstream of the probe.

The primer must have sufficient length so that it is capable of priming the synthesis of extension products in the presence of an agent for polymerization. The length and composition of the primer depends on many parameters, including, for example, the temperature at which the annealing reaction is conducted, proximity of the probe binding site to that of the primer, relative concentrations of the primer and probe and the particular nucleic acid composition of the probe. Typically the primer includes 15-30 nucleotides. However, the length of the primer may be more or less depending on the complexity of the primer binding site and the factors listed above.

Labels for Probes and Primers

The labels used for labeling the probes or primers of the current invention and which can provide the signal corresponding to the quantity of amplification product can take a variety of forms. As indicated above with regard to the 5' fluorogenic nuclease method, a fluorescent signal is one signal which can be measured. However, measurements may also be made, for example, by monitoring radioactivity, colorimetry, absorption, magnetic parameters, or enzymatic activity. Thus, labels which can be employed include, but are not limited to, fluorophores, chromophores, radioactive isotopes, electron dense reagents, enzymes, and ligands having specific binding partners (e.g., biotin-avidin).

Monitoring changes in fluorescence is a particularly useful way to monitor the accumulation of amplification products. A number of labels useful for attachment to probes or primers are commercially available including fluorescein and various fluorescein derivatives such as FAM, HEX, TET and JOE (all which are available from Applied Biosystems, Foster City, Calif.); lucifer yellow, and coumarin derivatives.

Labels may be attached to the probe or primer using a variety of techniques and can be attached at the 5' end, and/or the 3' end and/or at an internal nucleotide. The label can also be attached to spacer arms of various sizes which are attached to the probe or primer. These spacer arms are useful for obtaining a desired distance between multiple labels attached to the probe or primer.

In some instances, a single label may be utilized; whereas, in other instances, such as with the 5' fluorogenic nuclease assays for example, two or more labels are attached to the probe. In cases wherein the probe includes multiple labels, it is generally advisable to maintain spacing between the labels which is sufficient to permit separation of the labels during digestion of the probe through the 5'-3' nuclease activity of the nucleic acid polymerase.

Patients Exhibiting Symptoms of Disease

5 A number of diseases are associated with changes in the copy number of a certain gene. For patients having symptoms of a disease, the real-time PCR method can be used to determine if the patient has copy number alterations which are known to be linked with diseases that are associated with the symptoms the patient has.

prostaglandin E2 EP1 expression

10

prostaglandin E2 EP1 fusion proteins

15

Fusion proteins are useful for generating antibodies against prostaglandin E2 EP1 polypeptides and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with portions of prostaglandin E2 EP1 polypeptides. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.

20

25

A prostaglandin E2 EP1 fusion protein comprises two polypeptide segments fused together by means of a peptide bond. The first polypeptide segment can comprise at least 54, 75, 100, 125, 139, 150, 175, 200, 225, 250, or 275 contiguous amino acids of SEQ ID NO: 2 or of a biologically active variant, such as those described above. The first polypeptide segment also can comprise full-length prostaglandin E2 EP1.

30

The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion protein construction include, but are not limited to β galactosidase, β -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase

- 22 -

(CAT). Additionally, epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, herpes simplex virus (HSV) BP16 protein fusions and G-protein fusions (for example G(alpha)16, Gs, Gi). A fusion protein also can be engineered to contain a cleavage site located adjacent to the prostaglandin E2 EP1.

Preparation of Polynucleotides

A naturally occurring prostaglandin E2 EP1 polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated prostaglandin E2 EP1 polynucleotides. For example, restriction enzymes and probes can be used to isolate polynucleotide fragments which comprise prostaglandin E2 EP1 nucleotide sequences. Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.

prostaglandin E2 EP1 cDNA molecules can be made with standard molecular biology techniques, using prostaglandin E2 EP1 mRNA as a template. prostaglandin E2 EP1 cDNA molecules can thereafter be replicated using molecular biology techniques known in the art. An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or cDNA as a template.

Alternatively, synthetic chemistry techniques can be used to synthesize prostaglandin E2 EP1 polynucleotides. The degeneracy of the genetic code allows

alternate nucleotide sequences to be synthesized which will encode prostaglandin E2 EP1 having, for example, an amino acid sequence shown in SEQ ID NO: 2 or a biologically active variant thereof.

5 *Extending Polynucleotides*

Various PCR-based methods can be used to extend nucleic acid sequences encoding human prostaglandin E2 EP1, for example to detect upstream sequences of prostaglandin E2 EP1 gene such as promoters and regulatory elements. For example,
10 restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus. Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are
15 transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region. Primers can be designed using commercially available
20 software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and
25 used as a PCR template.

Another method which can be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. In this method, multiple restriction enzyme digestions
30 and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

- 24 -

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a
5 randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

Commercially available capillary electrophoresis systems can be used to analyze the
10 size or confirm the nucleotide sequence of PCR or sequencing products. For example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity can be converted to electrical signal using appropriate
15 equipment and software (e.g., GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

20

Obtaining Polypeptides

prostaglandin E2 EP1 can be obtained, for example, by purification from human cells, by expression of prostaglandin E2 EP1 polynucleotides, or by direct chemical
25 synthesis.

Protein Purification

prostaglandin E2 EP1 can be purified from any human cell which expresses the
30 receptor, including those which have been transfected with expression constructs which express prostaglandin E2 EP1. A purified prostaglandin E2 EP1 is separated

- 25 -

from other compounds which normally associate with prostaglandin E2 EP1 in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.

Expression of prostaglandin E2 EP1 Polynucleotides

To express prostaglandin E2 EP1, prostaglandin E2 EP1 polynucleotides can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding prostaglandin E2 EP1 and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination.

A variety of expression vector/host systems can be utilized to contain and express sequences encoding prostaglandin E2 EP1. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (*e.g.*, baculovirus), plant cell systems transformed with virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids), or animal cell systems.

The control elements or regulatory sequences are those non-translated regions of the vector - enhancers, promoters, 5' and 3' untranslated regions -- which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in

- 26 -

bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells. Promoters or enhancers derived from the genomes of plant cells
5 (e.g., heat shock, RUBISCO, and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) can be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding prostaglandin E2 EP1, vectors based on SV40 or EBV
10 can be used with an appropriate selectable marker.

Bacterial and Yeast Expression Systems

In bacterial systems, a number of expression vectors can be selected. For example,
15 when a large quantity of prostaglandin E2 EP1 is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding prostaglandin E2 EP1
20 can be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced. pIN vectors or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells
25 by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

Plant and Insect Expression Systems

If plant expression vectors are used, the expression of sequences encoding prostaglandin E2 EP1 can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used. These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection.

An insect system also can be used to express prostaglandin E2 EP1. For example, in one such system *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. Sequences encoding prostaglandin E2 EP1 can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of prostaglandin E2 EP1 will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which prostaglandin E2 EP1 can be expressed.

Mammalian Expression Systems

A number of viral-based expression systems can be used to express prostaglandin E2 EP1 in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding prostaglandin E2 EP1 can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing prostaglandin E2 EP1 in infected host cells [Engelhard, 1994]. If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

- 28 -

Human artificial chromosomes (HACs) also can be used to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (*e.g.*, liposomes, polycationic amino polymers, or vesicles). Specific initiation signals also can be used to achieve more efficient translation of sequences encoding prostaglandin E2 EP1. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding prostaglandin E2 EP1, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic.

Host Cells

A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed prostaglandin E2 EP1 in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (*e.g.*, CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.

- 29 -

Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express prostaglandin E2 EP1 can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced prostaglandin E2 EP1 sequences. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. Any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase [Logan, (1984)] and adenine phosphoribosyltransferase [Wigler, (1977)] genes which can be employed in *tk* or *aprt* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate [Lowy, (1980)], *npt* confers resistance to the aminoglycosides, neomycin and G-418 [Wigler, (1980)], and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively [Colbere-Garapin, 1981]. Additional selectable genes have been described. For example, *trpB* allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine. Visible markers such as anthocyanins, β -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system.

Detecting Polypeptide Expression

Although the presence of marker gene expression suggests that a prostaglandin E2 EP1 polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding prostaglandin E2 EP1 is inserted within a marker gene sequence, transformed cells containing sequences which

encode prostaglandin E2 EP1 can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding prostaglandin E2 EP1 under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression
5 of prostaglandin E2 EP1 polynucleotide.

Alternatively, host cells which contain a prostaglandin E2 EP1 polynucleotide and which express prostaglandin E2 EP1 can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to,
10 DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a polynucleotide sequence encoding prostaglandin E2 EP1 can be detected by
15 DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding prostaglandin E2 EP1. Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding prostaglandin E2 EP1 to detect transformants which contain a prostaglandin E2 EP1 polynucleotide.

20 A variety of protocols for detecting and measuring the expression of prostaglandin E2 EP1, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies
25 reactive to two non-interfering epitopes on prostaglandin E2 EP1 can be used, or a competitive binding assay can be employed.

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for
30 producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding prostaglandin E2 EP1 include oligolabeling, nick trans-

- 31 -

lation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding prostaglandin E2 EP1 can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes *in vitro* by addition of labeled
5 nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as
10 substrates, cofactors, inhibitors, magnetic particles, and the like.

Expression and Purification of Polypeptides

Host cells transformed with prostaglandin E2 EP1 polynucleotides can be cultured
15 under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing prostaglandin E2 EP1 polynucleotides can be designed to contain signal sequences which direct
20 secretion of soluble prostaglandin E2 EP1 through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound prostaglandin E2 EP1.

As discussed above, other constructions can be used to join a sequence encoding
25 prostaglandin E2 EP1 to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain
30 utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Inclusion of cleavable linker sequences such as those specific for

- 32 -

Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and prostaglandin E2 EP1 also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing prostaglandin E2 EP1 and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilized metal ion affinity chromatography) Maddox, (1983)], while the enterokinase cleavage site provides a means for purifying prostaglandin E2 EP1 from the fusion protein [Porath, (1992)].

10 *Chemical Synthesis*

Sequences encoding prostaglandin E2 EP1 can be synthesized, in whole or in part, using chemical methods well known in the art. Alternatively, prostaglandin E2 EP1 itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques. Protein synthesis can either be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Optionally, fragments of prostaglandin E2 EP1 can be separately synthesized and combined using chemical methods to produce a full-length molecule.

The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography. The composition of a synthetic prostaglandin E2 EP1 can be confirmed by amino acid analysis or sequencing. Additionally, any portion of the amino acid sequence of prostaglandin E2 EP1 can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.

Production of Altered Polypeptides

As will be understood by those of skill in the art, it may be advantageous to produce prostaglandin E2 EP1 polynucleotides possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences referred to herein can be engineered using methods generally known in the art to alter prostaglandin E2 EP1 polynucleotides for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

Antibodies

Any type of antibody known in the art can be generated to bind specifically to an epitope of prostaglandin E2 EP1.

"Antibody" as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab')₂, and Fv, which are capable of binding an epitope of prostaglandin E2 EP1. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, e.g., at least 15, 25, or 50 amino acid. An antibody which specifically binds to an epitope of prostaglandin E2 EP1 can be used therapeutically, as well as in immunochemical assays, such as Western blots,

- 34 -

ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the prostaglandin E2 EP1 immunogen.

Typically, an antibody which specifically binds to prostaglandin E2 EP1 provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay. Preferably, antibodies which specifically bind to prostaglandin E2 EP1 do not detect other proteins in immunochemical assays and can immunoprecipitate prostaglandin E2 EP1 from solution.

prostaglandin E2 EP1 can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, prostaglandin E2 EP1 can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending on the host species, various adjuvants can be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (e.g., aluminum hydroxide), and surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol). Among adjuvants used in humans, BCG (*bacilli Calmette-Guerin*) and *Corynebacterium parvum* are especially useful.

Monoclonal antibodies which specifically bind to prostaglandin E2 EP1 can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique [Roberge, (1995)].

- 35 -

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. Monoclonal and other antibodies also can be "humanized" to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues. Sequence differences between rodent antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grafting of entire complementarity determining regions. Antibodies which specifically bind to prostaglandin E2 EP1 can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.

Alternatively, techniques described for the production of single chain antibodies can be adapted using methods known in the art to produce single chain antibodies which specifically bind to prostaglandin E2 EP1. Antibodies with related specificity, but of distinct idiotypic composition, can be generated by chain shuffling from random combinatorial immunoglobulin libraries. Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template. Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught. A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology.

30

- 36 -

Antibodies which specifically bind to prostaglandin E2 EP1 also can be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents. Other types of antibodies can be constructed and used therapeutically in methods of the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.

Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which prostaglandin E2 EP1 is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.

Antisense Oligonucleotides

Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of prostaglandin E2 EP1 gene products in the cell.

Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such as alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates,

- 37 -

alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamide, carboxymethyl esters, carbonates, and phosphate triesters.

Modifications of prostaglandin E2 EP1 gene expression can be obtained by designing
5 antisense oligonucleotides which will form duplexes to the control, 5', or regulatory
regions of the prostaglandin E2 EP1 gene. Oligonucleotides derived from the
transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are
preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing
methodology. Triple helix pairing is useful because it causes inhibition of the ability
10 of the double helix to open sufficiently for the binding of polymerases, transcription
factors, or chaperons. Therapeutic advances using triplex DNA have been described
in the literature [Nicholls, (1993)]. An antisense oligonucleotide also can be
designed to block translation of mRNA by preventing the transcript from binding to
ribosomes.

15 Precise complementarity is not required for successful complex formation between
an antisense oligonucleotide and the complementary sequence of a prostaglandin E2
EP1 polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 3,
4, or 5 or more stretches of contiguous nucleotides which are precisely comple-
20 mentary to a prostaglandin E2 EP1 polynucleotide, each separated by a stretch of
contiguous nucleotides which are not complementary to adjacent prostaglandin E2
EP1 nucleotides, can provide sufficient targeting specificity for prostaglandin E2
EP1 mRNA. Preferably, each stretch of complementary contiguous nucleotides is at
least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening
25 sequences are preferably 1, 2, 3, or 4 nucleotides in length. One skilled in the art can
easily use the calculated melting point of an antisense-sense pair to determine the
degree of mismatching which will be tolerated between a particular antisense
oligonucleotide and a particular prostaglandin E2 EP1 polynucleotide sequence.
Antisense oligonucleotides can be modified without affecting their ability to
30 hybridize to a prostaglandin E2 EP1 polynucleotide. These modifications can be
internal or at one or both ends of the antisense molecule. For example, inter-

- 38 -

nucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose. Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well known in the art.

Ribozymes

Ribozymes are RNA molecules with catalytic activity [Uhlmann, (1987)]. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences. The coding sequence of a prostaglandin E2 EP1 polynucleotide can be used to generate ribozymes which will specifically bind to mRNA transcribed from a prostaglandin E2 EP1 polynucleotide. Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art. For example, the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target RNA.

Specific ribozyme cleavage sites within a prostaglandin E2 EP1 RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate

- 39 -

prostaglandin E2 EP1 RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. The nucleotide sequences shown in SEQ ID NO: 1 and its complement provide sources of suitable hybridization region sequences. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease prostaglandin E2 EP1 expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. A ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells (U.S. 5,641,673). Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

Screening / Screening Assays

Regulators

Regulators as used herein, refer to compounds that affect the activity of a prostaglandin E2 EP1 in vivo and/or in vivo. Regulators can be agonists and antagonists of a prostaglandin E2 EP1 polypeptide and can be compounds that exert their effect on the prostaglandin E2 EP1 activity via the expression, via post-

translational modifications or by other means. Agonists of prostaglandin E2 EP1 are molecules which, when bound to prostaglandin E2 EP1, increase or prolong the activity of prostaglandin E2 EP1. Agonists of prostaglandin E2 EP1 include proteins, nucleic acids, carbohydrates, small molecules, or any other molecule which
5 activate prostaglandin E2 EP1. Antagonists of prostaglandin E2 EP1 are molecules which, when bound to prostaglandin E2 EP1, decrease the amount or the duration of the activity of prostaglandin E2 EP1. Antagonists include proteins, nucleic acids, carbohydrates, antibodies, small molecules, or any other molecule which decrease the activity of prostaglandin E2 EP1.

10 The term "modulate", as it appears herein, refers to a change in the activity of prostaglandin E2 EP1 polypeptide. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of prostaglandin E2 EP1.

15 As used herein, the terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein recognized by the binding molecule (i.e., the antigenic determinant or epitope). For
20 example, if an antibody is specific for epitope "A" the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

25 The invention provides methods (also referred to herein as "screening assays") for identifying compounds which can be used for the treatment of hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-uological disorders and inflammation diseases. The methods entail the identification of candidate or test compounds or agents (e.g., peptides,
30 peptidomimetics, small molecules or other molecules) which bind to prostaglandin E2 EP1 and/or have a stimulatory or inhibitory effect on the biological activity of

- 41 -

prostaglandin E2 EP1 or its expression and then determining which of these compounds have an effect on symptoms or diseases regarding the hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-uological disorders and inflammation diseases in an *in vivo* assay.

Candidate or test compounds or agents which bind to prostaglandin E2 EP1 and/or have a stimulatory or inhibitory effect on the activity or the expression of prostaglandin E2 EP1 are identified either in assays that employ cells which express prostaglandin E2 EP1 on the cell surface (cell-based assays) or in assays with isolated prostaglandin E2 EP1 (cell-free assays). The various assays can employ a variety of variants of prostaglandin E2 EP1 (e.g., full-length prostaglandin E2 EP1, a biologically active fragment of prostaglandin E2 EP1, or a fusion protein which includes all or a portion of prostaglandin E2 EP1). Moreover, prostaglandin E2 EP1 can be derived from any suitable mammalian species (e.g., human prostaglandin E2 EP1, rat prostaglandin E2 EP1 or murine prostaglandin E2 EP1). The assay can be a binding assay entailing direct or indirect measurement of the binding of a test compound or a known prostaglandin E2 EP1 ligand to prostaglandin E2 EP1. The assay can also be an activity assay entailing direct or indirect measurement of the activity of prostaglandin E2 EP1. The assay can also be an expression assay entailing direct or indirect measurement of the expression of prostaglandin E2 EP1 mRNA or prostaglandin E2 EP1 protein. The various screening assays are combined with an *in vivo* assay entailing measuring the effect of the test compound on the symptoms of hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-uological disorders and inflammation diseases.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a membrane-bound (cell surface expressed) form of prostaglandin E2 EP1. Such assays can employ full-length prostaglandin E2 EP1, a biologically active fragment of prostaglandin E2 EP1,

or a fusion protein which includes all or a portion of prostaglandin E2 EP1. As described in greater detail below, the test compound can be obtained by any suitable means, e.g., from conventional compound libraries. Determining the ability of the test compound to bind to a membrane-bound form of prostaglandin E2 EP1 can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the prostaglandin E2 EP1 - expressing cell can be measured by detecting the labeled compound in a complex. For example, the test compound can be labelled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radio-emission or by scintillation counting. Alternatively, the test compound can be enzymatically labelled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

In a competitive binding format, the assay comprises contacting prostaglandin E2 EP1 expressing cell with a known compound which binds to prostaglandin E2 EP1 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the prostaglandin E2 EP1 expressing cell, wherein determining the ability of the test compound to interact with the prostaglandin E2 EP1 expressing cell comprises determining the ability of the test compound to preferentially bind the prostaglandin E2 EP1 expressing cell as compared to the known compound.

In another embodiment, the assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of prostaglandin E2 EP1 (e.g., full-length prostaglandin E2 EP1, a biologically active fragment of prostaglandin E2 EP1, or a fusion protein which includes all or a portion of prostaglandin E2 EP1) expressed on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the membrane-bound form of prostaglandin E2 EP1. Determining the ability of the test compound to modulate the activity of the membrane-bound form of prostaglandin E2 EP1 can be

accomplished by any method suitable for measuring the activity of prostaglandin E2 EP1, e.g., any method suitable for measuring the activity of a G-protein coupled receptor or other seven-transmembrane receptor (described in greater detail below). The activity of a seven-transmembrane receptor can be measured in a number of ways, not all of which are suitable for any given receptor. Among the measures of activity are: alteration in intracellular Ca^{2+} concentration, activation of phospholipase C, alteration in intracellular inositol triphosphate (IP_3) concentration, alteration in intracellular diacylglycerol (DAG) concentration, and alteration in intracellular adenosine cyclic 3', 5'-monophosphate (cAMP) concentration.

Determining the ability of the test compound to modulate the activity of prostaglandin E2 EP1 can be accomplished, for example, by determining the ability of prostaglandin E2 EP1 to bind to or interact with a target molecule. The target molecule can be a molecule with which prostaglandin E2 EP1 binds or interacts with in nature, for example, a molecule on the surface of a cell which expresses prostaglandin E2 EP1, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. The target molecule can be a component of a signal transduction pathway which facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a prostaglandin E2 EP1 ligand, through the cell membrane and into the cell. The target prostaglandin E2 EP1 molecule can be, for example, a second intracellular protein which has catalytic activity or a protein which facilitates the association of downstream signaling molecules with prostaglandin E2 EP1.

Determining the ability of prostaglandin E2 EP1 to bind to or interact with a target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of a polypeptide of the invention to bind to or interact with a target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular

- 44 -

second messenger of the target (e.g., intracellular Ca^{2+} , diacylglycerol, IP_3 , etc.), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the induction of a reporter gene (e.g., a regulatory element that is responsive to a polypeptide of the invention operably linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response.

The present invention also includes cell-free assays. Such assays involve contacting a form of prostaglandin E2 EP1 (e.g., full-length prostaglandin E2 EP1, a biologically active fragment of prostaglandin E2 EP1, or a fusion protein comprising all or a portion of prostaglandin E2 EP1) with a test compound and determining the ability of the test compound to bind to prostaglandin E2 EP1. Binding of the test compound to prostaglandin E2 EP1 can be determined either directly or indirectly as described above. In one embodiment, the assay includes contacting prostaglandin E2 EP1 with a known compound which binds prostaglandin E2 EP1 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with prostaglandin E2 EP1, wherein determining the ability of the test compound to interact with prostaglandin E2 EP1 comprises determining the ability of the test compound to preferentially bind to prostaglandin E2 EP1 as compared to the known compound.

The cell-free assays of the present invention are amenable to use of either a membrane-bound form of prostaglandin E2 EP1 or a soluble fragment thereof. In the case of cell-free assays comprising the membrane-bound form of the polypeptide, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of the polypeptide is maintained in solution. Examples of such solubilizing agents include but are not limited to non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton X-100, Triton X-114, Thesit, Isotridecypoly(ethylene glycol ether)_n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

In various embodiments of the above assay methods of the present invention, it may be desirable to immobilize prostaglandin E2 EP1 (or a prostaglandin E2 EP1 target molecule) to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to prostaglandin E2 EP1, or interaction of prostaglandin E2 EP1 with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase (GST) fusion proteins or glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical; St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or prostaglandin E2 EP1, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components and complex formation is measured either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of binding or activity of prostaglandin E2 EP1 can be determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either prostaglandin E2 EP1 or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated polypeptide of the invention or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, Ill.), and immobilized in the wells of streptavidin-coated plates (Pierce Chemical). Alternatively, antibodies reactive with prostaglandin E2 EP1 or target molecules but which do not interfere with binding of

- 46 -

the polypeptide of the invention to its target molecule can be derivatized to the wells of the plate, and unbound target or polypeptide of the invention trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of
5 complexes using antibodies reactive with prostaglandin E2 EP1 or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with prostaglandin E2 EP1 or target molecule.

The screening assay can also involve monitoring the expression of prostaglandin E2
10 EP1. For example, regulators of expression of prostaglandin E2 EP1 can be identified in a method in which a cell is contacted with a candidate compound and the expression of prostaglandin E2 EP1 protein or mRNA in the cell is determined. The level of expression of prostaglandin E2 EP1 protein or mRNA the presence of the candidate compound is compared to the level of expression of prostaglandin E2
15 EP1 protein or mRNA in the absence of the candidate compound. The candidate compound can then be identified as a regulator of expression of prostaglandin E2 EP1 based on this comparison. For example, when expression of prostaglandin E2 EP1 protein or mRNA protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is
20 identified as a stimulator of prostaglandin E2 EP1 protein or mRNA expression. Alternatively, when expression of prostaglandin E2 EP1 protein or mRNA is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of prostaglandin E2 EP1 protein or mRNA expression. The level of prostaglandin E2 EP1 protein or
25 mRNA expression in the cells can be determined by methods described below.

Binding Assays

For binding assays, the test compound is preferably a small molecule which binds to
30 and occupies the active site of prostaglandin E2 EP1 polypeptide, thereby making the ligand binding site inaccessible to substrate such that normal biological activity is

prevented. Examples of such small molecules include, but are not limited to, small peptides or peptide-like molecules. Potential ligands which bind to a polypeptide of the invention include, but are not limited to, the natural ligands of known prostaglandin E2 EP1 GPCRs and analogues or derivatives thereof.

5

In binding assays, either the test compound or the prostaglandin E2 EP1 polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase. Detection of a test compound which is bound to prostaglandin E2 EP1 polypeptide can then be accomplished, for example, by direct counting of radioemission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product. Alternatively, binding of a test compound to a prostaglandin E2 EP1 polypeptide can be determined without labeling either of the interactants. For example, a microphysiometer can be used to detect binding of a test compound with a prostaglandin E2 EP1 polypeptide. A microphysiometer (e.g., Cytosensor™) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and prostaglandin E2 EP1 [Haseloff, (1988)].

20

Determining the ability of a test compound to bind to prostaglandin E2 EP1 also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) [McConnell, (1992); Sjolander, (1991)]. BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore™). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

25

In yet another aspect of the invention, a prostaglandin E2 EP1-like polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay [Szabo,

30

(1995); U.S. 5,283,317), to identify other proteins which bind to or interact with prostaglandin E2 EP1 and modulate its activity.

5 The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. For example, in one construct, polynucleotide encoding prostaglandin E2 EP1 can be fused to a polynucleotide encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct a DNA sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact *in vivo* to form an protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with prostaglandin E2 EP1.

20 It may be desirable to immobilize either the prostaglandin E2 EP1 (or polynucleotide) or the test compound to facilitate separation of the bound form from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either the prostaglandin E2 EP1-like polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach prostaglandin E2 EP1-like polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds

are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to prostaglandin E2 EP1 (or a polynucleotide encoding for prostaglandin E2 EP1) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.

In one embodiment, prostaglandin E2 EP1 is a fusion protein comprising a domain that allows binding of prostaglandin E2 EP1 to a solid support. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the non-adsorbed prostaglandin E2 EP1; the mixture is then incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solid support also can be used in the screening assays of the invention. For example, either prostaglandin E2 EP1 (or a polynucleotide encoding prostaglandin E2 EP1) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated prostaglandin E2 EP1 (or a polynucleotide encoding biotinylated prostaglandin E2 EP1) or test compounds can be prepared from biotin-NHS (N-hydroxysuccinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated plates (Pierce Chemical). Alternatively, antibodies which specifically bind to prostaglandin E2 EP1, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the active site of prostaglandin E2 EP1, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.

- 50 -

Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to prostaglandin E2 EP1 polypeptide or test
5 compound, enzyme-linked assays which rely on detecting an activity of prostaglandin E2 EP1 polypeptide, and SDS gel electrophoresis under non-reducing conditions.

10 Screening for test compounds which bind to a prostaglandin E2 EP1 polypeptide or polynucleotide also can be carried out in an intact cell. Any cell which comprises a prostaglandin E2 EP1 polypeptide or polynucleotide can be used in a cell-based assay system. A prostaglandin E2 EP1 polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Binding of the test compound to prostaglandin E2 EP1 or a polynucleotide encoding
15 prostaglandin E2 EP1 is determined as described above.

Functional Assays

Test compounds can be tested for the ability to increase or decrease prostaglandin E2
20 EP1 activity of a prostaglandin E2 EP1 polypeptide. The prostaglandin E2 EP1 activity can be measured, for example, using methods described in the specific examples, below. prostaglandin E2 EP1 activity can be measured after contacting either a purified prostaglandin E2 EP1, a cell membrane preparation, or an intact cell with a test compound. A test compound which decreases prostaglandin E2 EP1
25 activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential agent for decreasing prostaglandin E2 EP1 activity. A test compound which increases prostaglandin E2 EP1 activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential agent for increasing prostaglandin E2 EP1 activity.

30

- 51 -

One such screening procedure involves the use of melanophores which are transfected to express prostaglandin E2 EP1. Such a screening technique is described in PCT WO 92/01810 published Feb. 6, 1992. Thus, for example, such an assay may be employed for screening for a compound which inhibits activation of the receptor polypeptide of the present invention by contacting the melanophore cells which encode the receptor with both the receptor ligand and a compound to be screened. Inhibition of the signal generated by the ligand indicates that a compound is a potential antagonist for the receptor, *i.e.*, inhibits activation of the receptor. The screen may be employed for identifying a compound which activates the receptor by contacting such cells with compounds to be screened and determining whether each compound generates a signal, *i.e.*, activates the receptor.

Other screening techniques include the use of cells which express prostaglandin E2 EP1 (for example, transfected CHO cells) in a system which measures extracellular pH changes caused by receptor activation [Iwabuchi, (1993)]. For example, compounds may be contacted with a cell which expresses the receptor polypeptide of the present invention and a second messenger response, *e.g.*, signal transduction or pH changes, can be measured to determine whether the potential compound activates or inhibits the receptor. Another such screening technique involves introducing RNA encoding prostaglandin E2 EP1 into *Xenopus* oocytes to transiently express the receptor. The receptor oocytes can then be contacted with the receptor ligand and a compound to be screened, followed by detection of inhibition or activation of a calcium signal in the case of screening for compounds which are thought to inhibit activation of the receptor.

Another screening technique involves expressing prostaglandin E2 EP1 in cells in which the receptor is linked to a phospholipase C or D. Such cells include endothelial cells, smooth muscle cells, embryonic kidney cells, etc. The screening may be accomplished as described above by quantifying the degree of activation of the receptor from changes in the phospholipase activity.

Gene Expression

In another embodiment, test compounds which increase or decrease prostaglandin E2 EP1 gene expression are identified. As used herein, the term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding prostaglandin E2 EP1, by northern analysis or relative PCR is indicative of the presence of nucleic acids encoding prostaglandin E2 EP1 in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding prostaglandin E2 EP1. The term "microarray", as used herein, refers to an array of distinct polynucleotides or oligonucleotides arrayed on a substrate, such as paper, nylon or any other type of membrane, filter, chip, glass slide, or any other suitable solid support. A prostaglandin E2 EP1 polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of prostaglandin E2 EP1 polynucleotide is determined. The level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound. The test compound can then be identified as a regulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.

The level of prostaglandin E2 EP1 mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or polypeptide. Either qualitative or quantitative methods can be used. The presence of polypeptide products of prostaglandin E2 EP1 polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry. Alter-

natively, polypeptide synthesis can be determined *in vivo*, in a cell culture, or in an *in vitro* translation system by detecting incorporation of labelled amino acids into prostaglandin E2 EP1.

5 Such screening can be carried out either in a cell-free assay system or in an intact cell. Any cell which expresses prostaglandin E2 EP1 polynucleotide can be used in a cell-based assay system. The prostaglandin E2 EP1 polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Either a primary culture or an established cell line can be used.

10

Test Compounds

Suitable test compounds for use in the screening assays of the invention can be obtained from any suitable source, e.g., conventional compound libraries. The test
15 compounds can also be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological
20 library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds [Lam, (1997)]. Examples of methods for the synthesis of molecular libraries can be found in the art. Libraries of compounds may be presented in solution or on beads, bacteria, spores, plasmids or phage.

25

Modeling of Regulators

Computer modeling and searching technologies permit identification of compounds, or the improvement of already identified compounds, that can modulate
30 prostaglandin E2 EP1 expression or activity. Having identified such a compound or composition, the active sites or regions are identified. Such active sites might

- 54 -

typically be ligand binding sites, such as the interaction domain of the ligand with prostaglandin E2 EP1. The active site can be identified using methods known in the art including, for example, from the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from study of complexes of the relevant
5 compound or composition with its natural ligand. In the latter case, chemical or X-ray crystallographic methods can be used to find the active site by finding where on the factor the complexed ligand is found.

Next, the three dimensional geometric structure of the active site is determined. This
10 can be done by known methods, including X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intramolecular distances. Any other experimental method of structure determination can be used to obtain partial or complete geometric structures. The geometric structures may be measured with a
15 complexed ligand, natural or artificial, which may increase the accuracy of the active site structure determined.

If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can be used to complete the structure or
20 improve its accuracy. Any recognized modeling method may be used, including parameterized models specific to particular biopolymers such as proteins or nucleic acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal ensembles, or combined models. For most types of models, standard molecular force fields, representing the forces between
25 constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or less accurate experimental structures can serve as constraints on the complete and more accurate structures computed by these modeling methods.

30 Finally, having determined the structure of the active site, either experimentally, by modeling, or by a combination, candidate modulating compounds can be identified.

by searching databases containing compounds along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These compounds found from this search are potential prostaglandin E2 EP1 modulating compounds.

Alternatively, these methods can be used to identify improved modulating compounds from an already known modulating compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modeling methods described above applied to the new composition. The altered structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be quickly evaluated to obtain modified modulating compounds or ligands of improved specificity or activity.

Therapeutic Indications and Methods

It was found by the present applicant that prostaglandin E2 EP1 is expressed in various human tissues.

Cardiovascular Disorders

Heart failure is defined as a pathophysiological state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failures such as high-output and low-output, acute and chronic, right-sided or left-sided, systolic or diastolic, independent of the underlying cause.

Myocardial infarction (MI) is generally caused by an abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously narrowed by arteriosclerosis. MI prophylaxis (primary and secondary prevention) is included as well as the acute treatment of MI and the prevention of complications.

5

Ischemic diseases are conditions in which the coronary flow is restricted resulting in a perfusion which is inadequate to meet the myocardial requirement for oxygen. This group of diseases includes stable angina, unstable angina and asymptomatic ischemia.

10

Arrhythmias include all forms of atrial and ventricular tachyarrhythmias, atrial tachycardia, atrial flutter, atrial fibrillation, atrio-ventricular reentrant tachycardia, preexcitation syndrome, ventricular tachycardia, ventricular flutter, ventricular fibrillation, as well as bradycardic forms of arrhythmias.

15

Hypertensive vascular diseases include primary as well as all kinds of secondary arterial hypertension, renal, endocrine, neurogenic, others. The genes may be used as drug targets for the treatment of hypertension as well as for the prevention of all complications arising from cardiovascular diseases.

20

Peripheral vascular diseases are defined as vascular diseases in which arterial and/or venous flow is reduced resulting in an imbalance between blood supply and tissue oxygen demand. It includes chronic peripheral arterial occlusive disease (PAOD), acute arterial thrombosis and embolism, inflammatory vascular disorders, Raynaud's phenomenon and venous disorders.

25

Atherosclerosis is a cardiovascular disease in which the vessel wall is remodeled, compromising the lumen of the vessel. The atherosclerotic remodeling process involves accumulation of cells, both smooth muscle cells and monocyte/macrophage inflammatory cells, in the intima of the vessel wall. These cells take up lipid, likely from the circulation, to form a mature atherosclerotic lesion. Although the formation

30

of these lesions is a chronic process, occurring over decades of an adult human life, the majority of the morbidity associated with atherosclerosis occurs when a lesion ruptures, releasing thrombogenic debris that rapidly occludes the artery. When such an acute event occurs in the coronary artery, myocardial infarction can ensue, and in
5 the worst case, can result in death.

The formation of the atherosclerotic lesion can be considered to occur in five overlapping stages such as migration, lipid accumulation, recruitment of inflammatory cells, proliferation of vascular smooth muscle cells, and extracellular matrix
10 deposition. Each of these processes can be shown to occur in man and in animal models of atherosclerosis, but the relative contribution of each to the pathology and clinical significance of the lesion is unclear.

Thus, a need exists for therapeutic methods and agents to treat cardiovascular
15 pathologies, such as atherosclerosis and other conditions related to coronary artery disease.

Cardiovascular diseases include but are not limited to disorders of the heart and the vascular system like congestive heart failure, myocardial infarction, ischemic
20 diseases of the heart, all kinds of atrial and ventricular arrhythmias, hypertensive vascular diseases, peripheral vascular diseases, and atherosclerosis.

Too high or too low levels of fats in the bloodstream, especially cholesterol, can cause long-term problems. The risk to develop atherosclerosis and coronary artery or carotid artery disease (and thus the risk of having a heart attack or stroke) increases
25 with the total cholesterol level increasing. Nevertheless, extremely low cholesterol levels may not be healthy. Examples of disorders of lipid metabolism are hyperlipidemia (abnormally high levels of fats (cholesterol, triglycerides, or both) in the blood, may be caused by family history of hyperlipidemia), obesity, a high-fat diet, lack of exercise, moderate to high alcohol consumption, cigarette smoking,
30 poorly controlled diabetes, and an underactive thyroid gland), hereditary hyper-

- 58 -

lipidemias (type I hyperlipoproteinemia (familial hyperchylomicronemia), type II hyperlipoproteinemia (familial hypercholesterolemia), type III hyperlipoproteinemia, type IV hyperlipoproteinemia, or type V hyperlipoproteinemia), hypolipoproteinemia, lipidoses (caused by abnormalities in the enzymes that metabolize fats),
5 Gaucher's disease, Niemann-Pick disease, Fabry's disease, Wolman's disease, cerebrotendinous xanthomatosis, sitosterolemia, Refsum's disease, or Tay-Sachs disease.

10 Kidney disorders may lead to hypertension or hypotension. Examples for kidney problems possibly leading to hypertension are renal artery stenosis, pyelonephritis, glomerulonephritis, kidney tumors, polycystic kidney disease, injury to the kidney, or radiation therapy affecting the kidney. Excessive urination may lead to hypotension.

15 The human prostaglandin e2, ep1 is highly expressed in the following cardiovascular related tissues: heart, heart atrium (right), heart atrium (left), HUVEC cells. Expression in the above mentioned tissues demonstrates that the human prostaglandin e2, ep1 or mRNA can be utilized to diagnose of cardiovascular diseases. Additionally the activity of the human prostaglandin e2, ep1 can be modulated to treat cardiovascular diseases.

20

Hematological Disorders

Hematological disorders comprise diseases of the blood and all its constituents as well as diseases of organs and tissues involved in the generation or degradation of all
25 the constituents of the blood. They include but are not limited to 1) Anemias, 2) Myeloproliferative Disorders, 3) Hemorrhagic Disorders, 4) Leukopenia, 5) Eosinophilic Disorders, 6) Leukemias, 7) Lymphomas, 8) Plasma Cell Dyscrasias, 9) Disorders of the Spleen in the course of hematological disorders. Disorders according to 1) include, but are not limited to anemias due to defective or deficient hem
30 synthesis, deficient erythropoiesis. Disorders according to 2) include, but are not limited to polycythemia vera, tumor-associated erythrocytosis, myelofibrosis,

thrombocythemia. Disorders according to 3) include, but are not limited to vasculitis, thrombocytopenia, heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, hereditary and acquired disorders of platelet function, hereditary coagulation disorders. Disorders according to 4) include, but are not limited to neutropenia, lymphocytopenia. Disorders according to 5) include, but are not limited to hypereosinophilia, idiopathic hypereosinophilic syndrome. Disorders according to 6) include, but are not limited to acute myeloic leukemia, acute lymphoblastic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome. Disorders according to 7) include, but are not limited to Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, mycosis fungoides cutaneous T-cell lymphoma. Disorders according to 8) include, but are not limited to multiple myeloma, macroglobulinemia, heavy chain diseases. In extension of the preceding idiopathic thrombocytopenic purpura, iron deficiency anemia, megaloblastic anemia (vitamin B12 deficiency), aplastic anemia, thalassemia, malignant lymphoma bone marrow invasion, malignant lymphoma skin invasion, hemolytic uremic syndrome, giant platelet disease are considered to be hematological diseases too.

The human prostaglandin e2, ep1 is highly expressed in the following tissues of the hematological system: leukocytes (peripheral blood), bone marrow, thymus, spleen, spleen liver cirrhosis. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue spleen liver cirrhosis and healthy tissue spleen demonstrates that the human prostaglandin e2, ep1 or mRNA can be utilized to diagnose of hematological diseases. Additionally the activity of the human prostaglandin e2, ep1 can be modulated to treat hematological disorders.

Gastrointestinal and Liver Diseases

Gastrointestinal diseases comprise primary or secondary, acute or chronic diseases of the organs of the gastrointestinal tract which may be acquired or inherited, benign or

malignant or metaplastic, and which may affect the organs of the gastrointestinal tract or the body as a whole. They comprise but are not limited to 1) disorders of the esophagus like achalasia, vigorous achalasia, dysphagia, cricopharyngeal incoordination, pre-esophageal dysphagia, diffuse esophageal spasm, globus sensation, Barrett's metaplasia, gastroesophageal reflux, 2) disorders of the stomach and duodenum like functional dyspepsia, inflammation of the gastric mucosa, gastritis, stress gastritis, chronic erosive gastritis, atrophy of gastric glands, metaplasia of gastric tissues, gastric ulcers, duodenal ulcers, neoplasms of the stomach, 3) disorders of the pancreas like acute or chronic pancreatitis, insufficiency of the exocrine or endocrine tissues of the pancreas like steatorrhea, diabetes, neoplasms of the exocrine or endocrine pancreas like 3.1) multiple endocrine neoplasia syndrome, ductal adenocarcinoma, cystadenocarcinoma, islet cell tumors, insulinoma, gastrinoma, carcinoid tumors, glucagonoma, Zollinger-Ellison syndrome, Vipoma syndrome, malabsorption syndrome, 4) disorders of the bowel like chronic inflammatory diseases of the bowel, Crohn's disease, ileus, diarrhea and constipation, colonic inertia, megacolon, malabsorption syndrome, ulcerative colitis, 4.1) functional bowel disorders like irritable bowel syndrome, 4.2) neoplasms of the bowel like familial polyposis, adenocarcinoma, primary malignant lymphoma, carcinoid tumors, Kaposi's sarcoma, polyps, cancer of the colon and rectum.

Liver diseases comprise primary or secondary, acute or chronic diseases or injury of the liver which may be acquired or inherited, benign or malignant, and which may affect the liver or the body as a whole. They comprise but are not limited to disorders of the bilirubin metabolism, jaundice, syndromes of Gilbert's, Crigler-Najjar, Dubin-Johnson and Rotor; intrahepatic cholestasis, hepatomegaly, portal hypertension, ascites, Budd-Chiari syndrome, portal-systemic encephalopathy, fatty liver, steatosis, Reye's syndrome, liver diseases due to alcohol, alcoholic hepatitis or cirrhosis, fibrosis and cirrhosis, fibrosis and cirrhosis of the liver due to inborn errors of metabolism or exogenous substances, storage diseases, syndromes of Gaucher's, Zellweger's, Wilson's - disease, acute or chronic hepatitis, viral hepatitis and its variants, inflammatory conditions of the liver due to viruses, bacteria, fungi,

protozoa, helminths; drug induced disorders of the liver, chronic liver diseases like primary sclerosing cholangitis, α_1 -antitrypsin-deficiency, primary biliary cirrhosis, postoperative liver disorders like postoperative intrahepatic cholestasis, hepatic granulomas, vascular liver disorders associated with systemic disease, benign
5 or malignant neoplasms of the liver, disturbance of liver metabolism in the new-born or prematurely born.

The human prostaglandin e2, ep1 is highly expressed in the following tissues of the gastroenterological system: stomach, colon, small intestine, rectum, liver, liver liver
10 cirrhosis. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue liver liver cirrhosis and healthy tissue liver demonstrates that the human prostaglandin e2, ep1 or mRNA can be utilized to diagnose of gastroenterological disorders. Additionally the activity of the human prostaglandin e2, ep1 can be modulated to treat gastroenterological disorders.

15

Endocrine System and Hormones

The endocrine system consists of a group of organs whose main function is to produce and secrete hormones directly into the bloodstream. The major organs of the
20 endocrine system are the hypothalamus, the pituitary gland, thyroid gland, the parathyroid glands, the islets of the pancreas, the adrenal glands, the testes, and the ovaries.

The hypothalamus secretes several hormones that stimulate the pituitary: Some
25 trigger the release of pituitary hormones; others suppress the release of pituitary hormones.

The pituitary gland coordinates many functions of the other endocrine glands, but some pituitary hormones have direct effects.

30

The insulin-secreting cells of the pancreas respond to glucose and fatty acids. Parathyroid cells respond to calcium and phosphate. The adrenal medulla (part of the adrenal gland) responds to direct stimulation by the parasympathetic nervous system.

5 When endocrine glands malfunction, hormone levels in the blood can become abnormally high or low, disrupting body functions. Many disorders are caused by malfunction of the endocrine system or hormones. Examples of such disorders are presented in the following.

10 Diabetes mellitus is a disorder in which blood levels of glucose are abnormally high because the body doesn't release or use insulin adequately.

People with type I diabetes mellitus (insulin-dependent diabetes) produce little or no insulin at all. In type I diabetes more than 90 percent of the insulin-producing cells
15 (beta cells) of the pancreas are permanently destroyed. The resulting insulin deficiency is severe, and to survive, a person with type I diabetes must regularly inject insulin.

In type II diabetes mellitus (non-insulin-dependent diabetes) the body develops
20 resistance to insulin effects, resulting in a relative insulin deficiency.

The pancreas has two major functions: to secrete fluid containing digestive enzymes into the duodenum and to secrete the hormones insulin and glucagon. Chronic pancreatitis is a long-standing inflammation of the pancreas. Eventually, the insulin-
25 secreting cells of the pancreas may be destroyed, gradually leading to diabetes. An insulinoma is a rare type of pancreatic tumor that secretes insulin. The symptoms of an insulinoma result from low blood glucose levels. A gastrinoma is a pancreatic tumor that produces excessive levels of the hormone gastrin, which stimulates the stomach to secrete acid and enzymes, causing peptic ulcers. The excess gastrin
30 secreted by the gastrinoma causes symptoms, called the Zollinger-Ellison syndrome.

A glucagonoma is a tumor that produces the hormone glucagon, which raises the level of glucose in the blood and produces a distinctive rash.

5 Diabetes insipidus is a disorder in which insufficient levels of antidiuretic hormone cause excessive thirst (polydipsia) and excessive production of very dilute urine (polyuria). Diabetes insipidus results from the decreased production of antidiuretic hormone (vasopressin).

10 The body has two adrenal glands. The medulla of the adrenal glands secretes hormones such as adrenaline (epinephrine) that affect blood pressure, heart rate, sweating, and other activities also regulated by the sympathetic nervous system. The cortex secretes many different hormones, including corticosteroids (cortisone-like hormones), androgens (male hormones), and mineralocorticoids, which control blood pressure and the levels of salt and potassium in the body.

15 A diseases characterized by underactive adrenal glands is Addison's disease (adrenocortical insufficiency).

20 Several disorders are characterized by overactive Adrenal Glands. The causes can be changes in the adrenal glands themselves or overstimulation by the pituitary gland. Examples of these diseases are listed in the following.

25 Overproduction of androgenic steroids (testosterone and similar hormones, leads to virilization), overproduction of corticosteroids (causes could be tumors of the pituitary or the adrenal gland, results in Cushing's syndrome), Nelson's syndrome (developed by people who have both adrenal glands removed, characterized by an enlargement of the pituitary gland), Overproduction of aldosterone (hyperaldosteronism), Conn's syndrome (hyperaldosterism caused by a tumor), pheochromocytoma (a tumor that originating from the adrenal gland's chromaffin cells, causing overproduction of catecholamines),

30

- 64 -

The thyroid is a small gland located under the Adam's apple. It secretes thyroid hormones, which control the metabolic rate. The thyroid gland traps iodine and processes it into thyroid hormones. The euthyroid sick syndrome is characterized by lack of conversion of the T4 form of thyroid hormone to the T3 form. Hyperthyroidism (overactive thyroid gland, production of too much hormone) may have several causes. Thyroiditis (an inflammation of the thyroid gland), typically leads to a phase of hyperthyroidism. The inflammation may damage the thyroid gland, so that in later stages the disease is characterized by transient or permanent underactivity (hypothyroidism). Toxic thyroid nodules (adenomas) often produce thyroid hormone in large quantities. Toxic multinodular goiter (Plummer's disease) is a disorder in which there are many nodules. Graves' disease (toxic diffuse goiter) is believed to be caused by an antibody that stimulates the thyroid to produce too much thyroid hormone. In toxic nodular goiter, one or more nodules in the thyroid produce too much thyroid hormone and aren't under the control of thyroid-stimulating hormone. Secondary hyperthyroidism may (rarely) be caused by a pituitary tumor that secretes too much thyroid-stimulating hormone, by resistance of the pituitary to thyroid hormone, which results in the pituitary gland secreting too much thyroid-stimulating hormone, or by a hydatidiform mole in women. Thyroid storm is a sudden extreme overactivity of the thyroid gland is a life-threatening emergency requiring prompt treatment.

Hypothyroidism is a condition in which the thyroid gland is underactive and produces too little thyroid hormone. Very severe hypothyroidism is called myxedema. In Hashimoto's thyroiditis (autoimmune thyroiditis) the thyroid gland is often enlarged, and hypothyroidism results because the gland's functioning areas are gradually destroyed. Rarer causes of hypothyroidism include some inherited disorders which are caused by abnormalities of the enzymes in thyroid cells. In other rare disorders, either the hypothalamus or the pituitary gland fails to secrete enough of the hormone needed to stimulate normal thyroid function.

- 65 -

Other examples of Thyroiditis are silent lymphocytic thyroiditis, Hashimoto's thyroiditis, or subacute granulomatous thyroiditis.

5 Thyroid cancer is any one of four main types of malignancy of the thyroid: papillary, follicular, anaplastic, or medullary.

10 The pituitary is a pea-sized gland that sits in a bony structure (sella turcica) at the base of the brain. The sella turcica protects the pituitary but allows very little room for expansion. If the pituitary enlarges, it tends to push upward, often pressing on the areas of the brain that carry signals from the eyes, possibly resulting in headaches or impaired vision. The pituitary gland has two distinct parts: the anterior (front) and the posterior (back) lobes. The anterior lobe produces (secretes) hormones that ultimately control the function of the thyroid gland, adrenal glands, and reproductive organs (ovaries and testes); milk production (lactation) in the breasts; and overall body growth. It also produces hormones that cause the skin to darken and that inhibit pain sensations. The posterior lobe produces hormones that regulate water balance, stimulate the let-down of milk from the breasts in lactating women, and stimulate contractions of the uterus.

20 Examples for disorders of the pituitary gland are Empty Sella Syndrome; hypopituitarism (an underactive pituitary gland); acromegaly, which is excessive growth caused by oversecretion of growth hormone, which is almost always caused by a benign pituitary tumor (adenoma); galactorrhea, which is the production of breast milk in men or in women who aren't breastfeeding, in both sexes, the most common cause of galactorrhea is a prolactin-producing tumor (prolactinoma) in the
25 pituitary gland.

30 The human prostaglandin e2, ep1 is highly expressed in the following tissues of the endocrinological system: adrenal gland, pancreas, pancreas liver cirrhosis. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue pancreas liver cirrhosis and healthy tissue pancreas

demonstrates that the human prostaglandin e2, ep1 or mRNA can be utilized to diagnose of endocrinological disorders. Additionally the activity of the human prostaglandin e2, ep1 can be modulated to treat endocrinological disorders.

5 *Disorders Related to Pulmology*

Asthma is thought to arise as a result of interactions between multiple genetic and environmental factors and is characterized by three major features: 1) intermittent and reversible airway obstruction caused by bronchoconstriction, increased mucus
10 production, and thickening of the walls of the airways that leads to a narrowing of the airways, 2) airway hyperresponsiveness, and 3) airway inflammation. Certain cells are critical to the inflammatory reaction of asthma and they include T cells and antigen presenting cells, B cells that produce IgE, and mast cells, basophils, eosinophils, and other cells that bind IgE. These effector cells accumulate at the site
15 of allergic reaction in the airways and release toxic products that contribute to the acute pathology and eventually to tissue destruction related to the disorder. Other resident cells, such as smooth muscle cells, lung epithelial cells, mucus-producing cells, and nerve cells may also be abnormal in individuals with asthma and may contribute to its pathology. While the airway obstruction of asthma, presenting
20 clinically as an intermittent wheeze and shortness of breath, is generally the most pressing symptom of the disease requiring immediate treatment, the inflammation and tissue destruction associated with the disease can lead to irreversible changes that eventually make asthma a chronic and disabling disorder requiring long-term management.

25

Chronic obstructive pulmonary (or airways) disease (COPD) is a condition defined physiologically as airflow obstruction that generally results from a mixture of emphysema and peripheral airway obstruction due to chronic bronchitis [Botstein, 1980]. Emphysema is characterised by destruction of alveolar walls leading to
30 abnormal enlargement of the air spaces of the lung. Chronic bronchitis is defined clinically as the presence of chronic productive cough for three months in each of

two successive years. In COPD, airflow obstruction is usually progressive and is only partially reversible. By far the most important risk factor for development of COPD is cigarette smoking, although the disease does also occur in non-smokers.

5 The human prostaglandin e2, ep1 is highly expressed in the following tissues of the respiratory system: leukocytes (peripheral blood), fetal lung, fetal lung fibroblast IMR-90 cells, lung, lung tumor, lung COPD, trachea. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue fetal lung fibroblast IMR-90 cells and healthy tissue fetal lung, between diseased tissue lung tumor and healthy tissue lung, between diseased tissue lung COPD and healthy tissue lung demonstrates that the human prostaglandin e2, ep1 or mRNA can be utilized to diagnose of respiratory diseases. Additionally the activity of the human prostaglandin e2, ep1 can be modulated to treat those diseases.

15 *Disorders Related to Urology*

Genitourinary disorders comprise benign and malign disorders of the organs constituting the genitourinary system of female and male, renal diseases like acute or chronic renal failure, immunologically mediated renal diseases like renal transplant rejection, lupus nephritis, immune complex renal diseases, glomerulopathies, nephritis, toxic nephropathy, obstructive uropathies like benign prostatic hyperplasia (BPH), neurogenic bladder syndrome, urinary incontinence like urge-, stress-, or overflow incontinence, pelvic pain, and erectile dysfunction.

25 The human prostaglandin e2, ep1 is highly expressed in the following urological tissues: prostate, prostate BPH, bladder, ureter, fetal kidney, kidney. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue prostate BPH and healthy tissue prostate demonstrates that the human prostaglandin e2, ep1 or mRNA can be utilized to diagnose of urological disorders. Additionally the activity of the human prostaglandin e2, ep1 can be modulated to treat urological disorders.

Metabolic Disorders

5 Metabolic diseases are defined as conditions which result from an abnormality in any of the chemical or biochemical transformations and their regulating systems essential to producing energy, to regenerating cellular constituents, to eliminating unneeded products arising from these processes, and to regulate and maintain homeostasis in a mammal regardless of whether acquired or the result of a genetic transformation. Depending on which metabolic pathway is involved, a single defective transformation or disturbance of its regulation may produce consequences that are narrow, involving a single body function, or broad, affecting many organs, organ-systems or the body as a whole. Diseases resulting from abnormalities related to the fine and coarse mechanisms that affect each individual transformation, its rate and direction or the availability of substrates like amino acids, fatty acids, carbohydrates, minerals, cofactors, hormones, regardless whether they are inborn or acquired, are well within the scope of the definition of a metabolic disease according to this application.

Metabolic diseases often are caused by single defects in particular biochemical pathways, defects that are due to the deficient activity of individual enzymes or molecular receptors leading to the regulation of such enzymes. Hence in a broader sense disturbances of the underlying genes, their products and their regulation lie well within the scope of this definition of a metabolic disease. For example, but not limited to, metabolic diseases may affect 1) biochemical processes and tissues ubiquitous all over the body, 2) the bone, 3) the nervous system, 4) the endocrine system, 5) the muscle including the heart, 6) the skin and nervous tissue, 7) the urogenital system, 8) the homeostasis of body systems like water and electrolytes. For example, but not limited to, metabolic diseases according to 1) comprise obesity, amyloidosis, disturbances of the amino acid metabolism like branched chain disease, hyperaminoacidemia, hyperaminoaciduria, disturbances of the metabolism of urea, hyperammonemia, mucopolysaccharidoses e.g. Maroteaux-Lamy syndrom, storage diseases like glycogen storage diseases and lipid storage diseases, glycogenesis

diseases like Cori's disease, malabsorption diseases like intestinal carbohydrate malabsorption, oligosaccharidase deficiency like maltase-, lactase-, sucrase-insufficiency, disorders of the metabolism of fructose, disorders of the metabolism of galactose, galactosaemia, disturbances of carbohydrate utilization like diabetes, hypoglycemia, disturbances of pyruvate metabolism, hypolipidemia, hypolipoproteinemia, hyperlipidemia, hyperlipoproteinemia, carnitine or carnitine acyl-transferase deficiency, disturbances of the porphyrin metabolism, porphyrias, disturbances of the purine metabolism, lysosomal diseases, metabolic diseases of nerves and nervous systems like gangliosidoses, sphingolipidoses, sulfatidoses, leucodystrophies, Lesch-Nyhan syndrome. For example, but not limited to, metabolic diseases according to 2) comprise osteoporosis, osteomalacia like osteoporosis, osteopenia, osteogenesis imperfecta, osteopetrosis, osteonecrosis, Paget's disease of bone, hypophosphatemia. For example, but not limited to, metabolic diseases according to 3) comprise cerebellar dysfunction, disturbances of brain metabolism like dementia, Alzheimer's disease, Huntington's chorea, Parkinson's disease, Pick's disease, toxic encephalopathy, demyelinating neuropathies like inflammatory neuropathy, Guillain-Barré syndrome. For example, but not limited to, metabolic diseases according to 4) comprise primary and secondary metabolic disorders associated with hormonal defects like any disorder stemming from either an hyperfunction or hypofunction of some hormone-secreting endocrine gland and any combination thereof. They comprise Sipple's syndrome, pituitary gland dysfunction and its effects on other endocrine glands, such as the thyroid, adrenals, ovaries, and testes, acromegaly, hyper- and hypothyroidism, euthyroid goiter, euthyroid sick syndrome, thyroiditis, and thyroid cancer, over- or underproduction of the adrenal steroid hormones, adrenogenital syndrome, Cushing's syndrome, Addison's disease of the adrenal cortex, Addison's pernicious anemia, primary and secondary aldosteronism, diabetes insipidus, carcinoid syndrome, disturbances caused by the dysfunction of the parathyroid glands, pancreatic islet cell dysfunction, diabetes, disturbances of the endocrine system of the female like estrogen deficiency, resistant ovary syndrome. For example, but not limited to, metabolic diseases according to 5) comprise muscle weakness, myotonia, Duchenne's and other muscular dystrophies,

- 70 -

dystrophia myotonica of Steinert, mitochondrial myopathies like disturbances of the catabolic metabolism in the muscle, carbohydrate and lipid storage myopathies, glycogenoses, myoglobinuria, malignant hyperthermia, polymyalgia rheumatica, dermatomyositis, primary myocardial disease, cardiomyopathy. For example, but not limited to, metabolic diseases according to 6) comprise disorders of the ectoderm, neurofibromatosis, scleroderma and polyarteritis, Louis-Bar syndrome, von Hippel-Lindau disease, Sturge-Weber syndrome, tuberous sclerosis, amyloidosis, porphyria. For example, but not limited to, metabolic diseases according to 7) comprise sexual dysfunction of the male and female. For example, but not limited to, metabolic diseases according to 8) comprise confused states and seizures due to inappropriate secretion of antidiuretic hormone from the pituitary gland, Liddle's syndrome, Bartter's syndrome, Fanconi's syndrome, renal electrolyte wasting, diabetes insipidus.

The human prostaglandin e2, ep1 is highly expressed in the following metabolic disease related tissues: pancreas, pancreas liver cirrhosis, liver liver cirrhosis. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue pancreas liver cirrhosis and healthy tissue pancreas, between diseased tissue liver liver cirrhosis and healthy tissue liver demonstrates that the human prostaglandin e2, ep1 or mRNA can be utilized to diagnose of metabolic diseases. Additionally the activity of the human prostaglandin e2, ep1 can be modulated to treat metabolic diseases.

Applications

The present invention provides for both prophylactic and therapeutic methods for cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases.

The regulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of prostaglandin E2 EP1. An agent that modulates activity can be an agent as described herein, such as a nucleic acid or a

- 71 -

protein, a naturally-occurring cognate ligand of the polypeptide, a peptide, a peptidomimetic, or any small molecule. In one embodiment, the agent stimulates one or more of the biological activities of prostaglandin E2 EP1. Examples of such stimulatory agents include the active prostaglandin E2 EP1 and nucleic acid molecules encoding a portion of prostaglandin E2 EP1. In another embodiment, the agent inhibits one or more of the biological activities of prostaglandin E2 EP1. Examples of such inhibitory agents include antisense nucleic acid molecules and antibodies. These regulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by unwanted expression or activity of prostaglandin E2 EP1 or a protein in the prostaglandin E2 EP1 signaling pathway. In one embodiment, the method involves administering an agent like any agent identified or being identifiable by a screening assay as described herein, or combination of such agents that modulate say upregulate or downregulate the expression or activity of prostaglandin E2 EP1 or of any protein in the prostaglandin E2 EP1 signaling pathway. In another embodiment, the method involves administering a regulator of prostaglandin E2 EP1 as therapy to compensate for reduced or undesirably low expression or activity of prostaglandin E2 EP1 or a protein in the prostaglandin E2 EP1 signaling pathway.

Stimulation of activity or expression of prostaglandin E2 EP1 is desirable in situations in which activity or expression is abnormally low and in which increased activity is likely to have a beneficial effect. Conversely, inhibition of activity or expression of prostaglandin E2 EP1 is desirable in situations in which activity or expression of prostaglandin E2 EP1 is abnormally high and in which decreasing its activity is likely to have a beneficial effect.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

Pharmaceutical Compositions

5 This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

10 The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharma-
15 ceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

20 The invention includes pharmaceutical compositions comprising a regulator of prostaglandin E2 EP1 expression or activity (and/or a regulator of the activity or expression of a protein in the prostaglandin E2 EP1 signaling pathway) as well as methods for preparing such compositions by combining one or more such regulators and a pharmaceutically acceptable carrier. Also within the invention are pharma-
25 ceutical compositions comprising a regulator identified using the screening assays of the invention packaged with instructions for use. For regulators that are antagonists of prostaglandin E2 EP1 activity or which reduce prostaglandin E2 EP1 expression, the instructions would specify use of the pharmaceutical composition for treatment of hematological and cardiovascular diseases, disorders of the peripheral and central
30 nervous system, COPD, asthma, genito-urological disorders and inflammation diseases. For regulators that are agonists of prostaglandin E2 EP1 activity or

increase prostaglandin E2 EP1 expression, the instructions would specify use of the pharmaceutical composition for treatment of hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders and inflammation diseases.

5

An antagonist of prostaglandin E2 EP1 may be produced using methods which are generally known in the art. In particular, purified prostaglandin E2 EP1 may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind prostaglandin E2 EP1. Antibodies to prostaglandin E2 EP1 may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies like those which inhibit dimer formation are especially preferred for therapeutic use.

15

In another embodiment of the invention, the polynucleotides encoding prostaglandin E2 EP1, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding prostaglandin E2 EP1 may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding prostaglandin E2 EP1. Thus, complementary molecules or fragments may be used to modulate prostaglandin E2 EP1 activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding prostaglandin E2 EP1.

20

25

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express

30

nucleic acid sequence complementary to the polynucleotides of the gene encoding prostaglandin E2 EP1. These techniques are described, for example, in [Scott and Smith (1990) Science 249:386-390].

- 5 Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

10 An additional embodiment of the invention relates to the administration of a pharmaceutical composition containing prostaglandin E2 EP1 in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of prostaglandin E2 EP1, antibodies to prostaglandin E2 EP1, and mimetics, agonists, antagonists, or inhibitors of prostaglandin E2 EP1. The compositions may be administered alone or in
15 combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

20 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or
25 suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and
30 agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be

adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

5 Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EMTM (BASF, Parsippany, N.J.) or phosphate
10 buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a
15 pharmaceutically acceptable polyol like glycerol, propylene glycol, liquid polyethylene glycol, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial
20 and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for
25 example, aluminum monostearate and gelatin. Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a
30 sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the

preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

5 Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the
10 fluid carrier is applied orally and swished and expectorated or swallowed.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a
15 binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

20 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

25 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished
30 through the use of nasal sprays or suppositories. For transdermal administration, the

- 77 -

active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

5 The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

10 In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and
15 Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. 4,522,811.

20 It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required
25 pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

30

- 78 -

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration. For pharmaceutical compositions which include an antagonist of prostaglandin E2 EP1 activity, a compound which reduces expression of prostaglandin E2 EP1, or a compound which reduces expression or activity of a protein in the prostaglandin E2 EP1 signaling pathway or any combination thereof, the instructions for administration will specify use of the composition for hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders and inflammation diseases. For pharmaceutical compositions which include an agonist of prostaglandin E2 EP1 activity, a compound which increases expression of prostaglandin E2 EP1, or a compound which increases expression or activity of a protein in the prostaglandin E2 EP1 signaling pathway or any combination thereof, the instructions for administration will specify use of the composition for hematological and cardiovascular diseases, disorders of the peripheral and central nervous system, COPD, asthma, genito-urological disorders and inflammation diseases.

Diagnostics

In another embodiment, antibodies which specifically bind prostaglandin E2 EP1 may be used for the diagnosis of disorders characterized by the expression of prostaglandin E2 EP1, or in assays to monitor patients being treated with prostaglandin E2 EP1 or agonists, antagonists, and inhibitors of prostaglandin E2 EP1. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for prostaglandin E2 EP1 include methods which utilize the antibody and a label to detect prostaglandin E2 EP1 in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent joining with a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring prostaglandin E2 EP1, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of prostaglandin E2 EP1 expression. Normal or standard values for prostaglandin E2 EP1 expression are established by combining body fluids or cell
5 extracts taken from normal mammalian subjects, preferably human, with antibody to prostaglandin E2 EP1 under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, preferably by photometric means. Quantities of prostaglandin E2 EP1 expressed in subject samples from biopsied tissues are compared with the standard values. Deviation
10 between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding prostaglandin E2 EP1 may be used for diagnostic purposes. The polynucleotides which may be
15 used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of prostaglandin E2 EP1 may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of prostaglandin E2 EP1, and to monitor
20 regulation of prostaglandin E2 EP1 levels during therapeutic intervention.

Polynucleotide sequences encoding prostaglandin E2 EP1 may be used for the diagnosis of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and
25 metabolic diseases associated with expression of prostaglandin E2 EP1. The polynucleotide sequences encoding prostaglandin E2 EP1 may be used in Southern, Northern, or dot-blot analysis, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and ELISA assays; and in microarrays utilizing fluids or tissues from patient biopsies to detect altered prostaglandin E2 EP1 expression.
30 Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding prostaglandin E2 EP1 may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding prostaglandin E2 EP1 may be labelled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding prostaglandin E2 EP1 in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases associated with expression of prostaglandin E2 EP1, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding prostaglandin E2 EP1, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method,

large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with prostaglandin E2 EP1, or fragments thereof, and washed. Bound prostaglandin E2 EP1 is then detected by methods well known in the art. Purified prostaglandin E2 EP1 can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding prostaglandin E2 EP1 specifically compete with a test compound for binding prostaglandin E2 EP1. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with prostaglandin E2 EP1.

G-protein coupled receptors are ubiquitous in the mammalian host and are responsible for many biological functions, including many pathologies. Accordingly, it is desirable to find compounds and drugs which stimulate a G-protein coupled receptor on the one hand and which can inhibit the function of a G-protein coupled receptor on the other hand. For example, compounds which activate the G-protein coupled receptor may be employed for therapeutic purposes, such as the treatment of asthma, Parkinson's disease, acute heart failure, urinary retention, and osteoporosis. In particular, compounds which activate the receptors of the present invention are useful in treating various cardiovascular ailments such as caused by the lack of pulmonary blood flow or hypertension. In addition these compounds may also be used in treating various physiological disorders relating to abnormal control of fluid and electrolyte homeostasis and in diseases associated with abnormal angiotensin-induced aldosterone secretion.

In general, compounds which inhibit activation of the G-protein coupled receptor may be employed for a variety of therapeutic purposes, for example, for the treatment of hypotension and/or hypertension, angina pectoris, myocardial infarction, ulcers,

asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders including schizophrenia, manic excitement, depression, delirium, dementia or severe mental retardation, dyskinesias, such as Huntington's disease or Tourett's syndrome, among others. Compounds which inhibit G-protein coupled receptors
5 have also been useful in reversing endogenous anorexia and in the control of bulimia.

Determination of a Therapeutically Effective Dose

The determination of a therapeutically effective dose is well within the capability of
10 those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which increases or decreases prostaglandin E2 EP1 activity relative to prostaglandin E2 EP1 activity which occurs in the absence of the therapeutically effective dose. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice,
15 rabbits, dogs, or pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

Therapeutic efficacy and toxicity, e.g., ED₅₀ (the dose therapeutically effective in
20 50% of the population) and LD₅₀ (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD₅₀/ED₅₀. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture
25 assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. The exact dosage will be determined by the
30 practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or

- 83 -

to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts can vary from 0.1 micrograms to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc. If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either *ex vivo* or *in vivo* using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun", and DEAE- or calcium phosphate-mediated transfection.

If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above. Preferably, a reagent reduces expression of prostaglandin E2 EP1 gene or the activity of prostaglandin E2 EP1 by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of prostaglandin E2 EP1 gene or the activity of prostaglandin E2 EP1 can be assessed using methods well known in the art, such as hybridization of nucleotide probes to

prostaglandin E2 EP1-specific mRNA, quantitative RT-PCR, immunologic detection of prostaglandin E2 EP1, or measurement of prostaglandin E2 EP1 activity.

5 In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described
10 above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects. Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

15 Nucleic acid molecules of the invention are those nucleic acid molecules which are contained in a group of nucleic acid molecules consisting of (i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, (ii) nucleic acid molecules comprising the sequence of SEQ ID NO: 1, (iii)
20 nucleic acid molecules having the sequence of SEQ ID NO: 1, (iv) nucleic acid molecules the complementary strand of which hybridizes under stringent conditions to a nucleic acid molecule of (i), (ii), or (iii); and (v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid molecule of (iii) due to the degeneracy of the genetic code, wherein the polypeptide encoded by said nucleic
25 acid molecule has prostaglandin E2 EP1 activity.

Polypeptides of the invention are those polypeptides which are contained in a group of polypeptides consisting of (i) polypeptides having the sequence of SEQ ID NO: 2, (ii) polypeptides comprising the sequence of SEQ ID NO: 2, (iii) polypeptides
30 encoded by nucleic acid molecules of the invention and (iv) polypeptides which

show at least 99%, 98%, 95%, 90%, or 80% homology with a polypeptide of (i), (ii), or (iii), wherein said purified polypeptide has prostaglandin E2 EP1 activity.

5 An object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of (i) contacting a test compound with a prostaglandin E2 EP1 polypeptide, (ii) detect binding of said test compound to said
10 prostaglandin E2 EP1 polypeptide. E.g., compounds that bind to the prostaglandin E2 EP1 polypeptide are identified potential therapeutic agents for such a disease.

Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of
15 cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of (i) determining the activity of a prostaglandin E2 EP1 polypeptide at a certain concentration of a test compound or in the absence of said test compound, (ii) determining the activity of said polypeptide at a different
20 concentration of said test compound. E.g., compounds that lead to a difference in the activity of the prostaglandin E2 EP1 polypeptide in (i) and (ii) are identified potential therapeutic agents for such a disease.

Another object of the invention is a method of screening for therapeutic agents useful
25 in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of (i) determining the activity of a prostaglandin E2 EP1 polypeptide at a certain concentration of a test compound, (ii) determining
30 the activity of a prostaglandin E2 EP1 polypeptide at the presence of a compound known to be a regulator of a prostaglandin E2 EP1 polypeptide. E.g., compounds

- 86 -

that show similar effects on the activity of the prostaglandin E2 EP1 polypeptide in (i) as compared to compounds used in (ii) are identified potential therapeutic agents for such a disease.

- 5 Other objects of the invention are methods of the above, wherein the step of contacting is in or at the surface of a cell.

Other objects of the invention are methods of the above, wherein the cell is in vitro.

- 10 Other objects of the invention are methods of the above, wherein the step of contacting is in a cell-free system.

Other objects of the invention are methods of the above, wherein the polypeptide is coupled to a detectable label.

- 15 Other objects of the invention are methods of the above, wherein the compound is coupled to a detectable label.

- 20 Other objects of the invention are methods of the above, wherein the test compound displaces a ligand which is first bound to the polypeptide.

Other objects of the invention are methods of the above, wherein the polypeptide is attached to a solid support.

- 25 Other objects of the invention are methods of the above, wherein the compound is attached to a solid support.

- 30 Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases

- 87 -

in a mammal comprising the steps of (i) contacting a test compound with a prostaglandin E2 EP1 polynucleotide, (ii) detect binding of said test compound to said prostaglandin E2 EP1 polynucleotide. Compounds that, e.g., bind to the prostaglandin E2 EP1 polynucleotide are potential therapeutic agents for the treatment of such diseases.

Another object of the invention is the method of the above, wherein the nucleic acid molecule is RNA.

Another object of the invention is a method of the above, wherein the contacting step is in or at the surface of a cell.

Another object of the invention is a method of the above, wherein the contacting step is in a cell-free system.

Another object of the invention is a method of the above, wherein the polynucleotide is coupled to a detectable label.

Another object of the invention is a method of the above, wherein the test compound is coupled to a detectable label.

Another object of the invention is a method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of (i) determining the amount of a prostaglandin E2 EP1 polynucleotide in a sample taken from said mammal, (ii) determining the amount of prostaglandin E2 EP1 polynucleotide in healthy and/or diseased mammal. A disease is diagnosed, e.g., if there is a substantial similarity in the amount of prostaglandin E2 EP1 polynucleotide in said test mammal as compared to a diseased mammal.

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising
5 a therapeutic agent which binds to a prostaglandin E2 EP1 polypeptide.

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal
10 diseases, endocrinological diseases and metabolic diseases in a mammal comprising a therapeutic agent which regulates the activity of a prostaglandin E2 EP1 polypeptide.

Another object of the invention is a pharmaceutical composition for the treatment of
15 a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising a therapeutic agent which regulates the activity of a prostaglandin E2 EP1 polypeptide, wherein said therapeutic agent is (i) a small molecule, (ii) an RNA
20 molecule, (iii) an antisense oligonucleotide, (iv) a polypeptide, (v) an antibody, or (vi) a ribozyme.

Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal
25 diseases, endocrinological diseases and metabolic diseases in a mammal comprising a prostaglandin E2 EP1 polynucleotide.

Another object of the invention is a pharmaceutical composition for the treatment of
30 a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal

diseases, endocrinological diseases and metabolic diseases in a mammal comprising a prostaglandin E2 EP1 polypeptide.

5 Another object of the invention is the use of regulators of a prostaglandin E2 EP1 for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal.

10 Another object of the invention is a method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of (i) identifying a regulator of
15 prostaglandin E2 EP1, (ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal; and (iii) combining of said regulator with an acceptable pharmaceutical
20 carrier.

Another object of the invention is the use of a regulator of prostaglandin E2 EP1 for the regulation of prostaglandin E2 EP1 activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory
25 diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases.

The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting
30 the invention.

Examples

Example 1: Search for homologous sequences in public sequence data bases

5 The degree of homology can readily be calculated by known methods. Preferred methods to determine homology are designed to give the largest match between the sequences tested. Methods to determine homology are codified in publicly available computer programs such as BestFit, BLASTP, BLASTN, and FASTA. The BLAST programs are publicly available from NCBI and other sources in the internet.

10

For prostaglandin E2 EP1 the following hits to known sequences were identified by using the BLAST algorithm [Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ; Nucleic Acids Res 1997 Sep 1; 25(17): 3389-402] and the following set of parameters: matrix = BLOSUM62 and low complexity filter. The following databases were searched: NCBI (non-redundant database) and DERWENT patent database (Geneseq).

15

The following hits were found:

20

>emb|AX578057.1| Sequence 179 from Patent WO02081745, Length = 1376, Score = 2646 bits (1376), Expect = 0.0, Identities = 1376/1376 (100%)

25

>emb|AX549003.1| Sequence 288 from Patent WO02061087, Length = 1376, Score = 2646 bits (1376), Expect = 0.0, Identities = 1376/1376 (100%)

30

>ref|NM_000955.1| Homo sapiens prostaglandin E receptor 1 (subtype EP1), 42kDa PTGER1), mRNA, Length = 1376, Score = 2646 bits (1376), Expect = 0.0, Identities = 1376/1376 (100%)

35

>gb|L22647.1|HUMG Human prostaglandin receptor ep1 subtype mRNA, complete cds, Length = 1376, Score = 2646 bits (1376), Expect = 0.0, Identities = 1376/1376 (100%)

- 91 -

- >gb|AR224022.1| Sequence 3 from patent US 6440680, Length = 1394, Score = 2630 bits (1368), Expect = 0.0, Identities = 1375/1376 (99%), Gaps = 1/1376 (0%)
- 5 >gb|AR086516.1|AR086516 Sequence 3 from patent US 5985597, Length = 1394, Score = 2630 bits (1368), Expect = 0.0, Identities = 1375/1376 (99%), Gaps = 1/1376 (0%)
- 10 >gb|BC039034.1| Homo sapiens, Similar to prostaglandin E receptor 1 (subtype EP1), 42kDa, clone IMAGE:5748278, mRNA, Length = 1453, Score = 2609 bits (1357), Expect = 0.0, Identities = 1365/1369 (99%)
- >emb|AX280933.1| Sequence 556 from Patent WO0177172, Length = 1209, Score = 2313 bits (1203), Expect = 0.0, Identities = 1207/1209 (99%)
- 15 >dbj|BD079086.1| Diagnostic method, Length = 3918, Score = 1834 bits (954), Expect = 0.0, Identities = 960/963 (99%)
- >gb|AC008569.7| Homo sapiens chromosome 19 clone CTC-548K16, complete sequence, Length = 227245, Score = 1834 bits (954), Expect = 0.0, Identities = 960/963 (99%)
- 20 >gb|AF266477.1|AF266477 Canis familiaris EP1 prostanoid receptor gene, complete cds, Length = 1974, Score = 1148 bits (597), Expect = 0.0, Identities = 846/963 (87%), Gaps = 21/963 (2%)
- 25

Example 2: Expression profiling

30 Total cellular RNA was isolated from cells by one of two standard methods: 1) guanidine isothiocyanate/Cesium chloride density gradient centrifugation [Kellogg, (1990)]; or with the Tri-Reagent protocol according to the manufacturer's specifications (Molecular Research Center, Inc., Cincinnati, Ohio). Total RNA prepared by the Tri-reagent protocol was treated with DNase I to remove genomic DNA contamination.

35

For relative quantitation of the mRNA distribution of prostaglandin E2 EP1, total RNA from each cell or tissue source was first reverse transcribed. 85 µg of total

- 92 -

RNA was reverse transcribed using 1 μ mole random hexamer primers, 0.5 mM each of dATP, dCTP, dGTP and dTTP (Qiagen, Hilden, Germany), 3000 U RnaseQut (Invitrogen, Groningen, Netherlands) in a final volume of 680 μ l. The first strand synthesis buffer and Omniscript reverse transcriptase (2 u/ μ l) were from (Qiagen, Hilden, Germany). The reaction was incubated at 37°C for 90 minutes and cooled on ice. The volume was adjusted to 6800 μ l with water, yielding a final concentration of 12.5 ng/ μ l of starting RNA.

For relative quantitation of the distribution of prostaglandin E2 EP1 mRNA in cells and tissues the Applied Biosystems 7900 HT Sequence Detection system or Biorad iCycler was used according to the manufacturer's specifications and protocols. PCR reactions were set up to quantitate prostaglandin E2 EP1 and the housekeeping genes HPRT (hypoxanthine phosphoribosyltransferase), GAPDH (glyceraldehyde-3-phosphate dehydrogenase), β -actin, and others. Forward and reverse primers and probes for prostaglandin E2 EP1 were designed using the Perkin Elmer ABI Primer ExpressTM software and were synthesized by TibMolBiol (Berlin, Germany). The prostaglandin E2 EP1 forward primer sequence was: Primer1 (SEQ ID NO: 3). The prostaglandin E2 EP1 reverse primer sequence was Primer2 (SEQ ID NO: 4). Probe1 (SEQ ID NO: 5), labelled with FAM (carboxyfluorescein succinimidyl ester) as the reporter dye and TAMRA (carboxytetramethylrhodamine) as the quencher, is used as a probe for prostaglandin E2 EP1. The following reagents were prepared in a total of 25 μ l : 1x TaqMan buffer A, 5.5 mM MgCl₂, 200 nM of dATP, dCTP, dGTP, and dUTP, 0.025 U/ μ l AmpliTaq GoldTM, 0.01 U/ μ l AmpErase and Probe1 (SEQ ID NO: 4), prostaglandin E2 EP1 forward and reverse primers each at 200 nM, 200 nM prostaglandin E2 EP1 FAM/TAMRA-labelled probe, and 5 μ l of template cDNA. Thermal cycling parameters were 2 min at 50°C, followed by 10 min at 95°C, followed by 40 cycles of melting at 95°C for 15 sec and annealing/extending at 60°C for 1 min.

Calculation of corrected CT values

The CT (threshold cycle) value is calculated as described in the "Quantitative determination of nucleic acids" section. The CF-value (factor for threshold cycle correction) is calculated as follows :

1. PCR reactions were set up to quantitate the housekeeping genes (HKG) for each cDNA sample.
2. CT_{HKG} -values (threshold cycle for housekeeping gene) were calculated as described in the "Quantitative determination of nucleic acids" section.
3. CT_{HKG} -mean values (CT mean value of all HKG tested on one cDNAs) of all HKG for each cDNA are calculated (n = number of HKG):

$$CT_{HKG-n}\text{-mean value} = (CT_{HKG1}\text{-value} + CT_{HKG2}\text{-value} + \dots + CT_{HKG-n}\text{-value}) / n$$
4. CT_{panel} mean value (CT mean value of all HKG in all tested cDNAs) =

$$(CT_{HKG1}\text{-mean value} + CT_{HKG2}\text{-mean value} + \dots + CT_{HKG-y}\text{-mean value}) / y$$
 (y = number of cDNAs)
5. CF_{cDNA-n} (correction factor for cDNA n) = $CT_{panel}\text{-mean value} - CT_{HKG-n}\text{-mean value}$
6. CT_{cDNA-n} (CT value of the tested gene for the cDNA n) + CF_{cDNA-n} (correction factor for cDNA n) = $CT_{cor-cDNA-n}$ (corrected CT value for a gene on cDNA n)

Calculation of relative expression

Definition : highest $CT_{cor-cDNA-n} \neq 40$ is defined as $CT_{cor-cDNA} [high]$

Relative Expression = $2^{(CT_{cor-cDNA}[high] - CT_{cor-cDNA-n})}$

5

Tissues

The expression of prostaglandin E2 EP1 was investigated in the tissues listed in table 1.

10

Expression profile

The results of the the mRNA-quantification (expression profiling) is shown in Table 1.

15

Table 1: *Relative expression of prostaglandin E2 EP1 in various human tissues*

	<u>Tissue</u>	<u>Relative Expression</u>
20	fetal heart	11
	heart	556
	pericardium	92
	heart atrium (right)	127
	heart atrium (left)	396
25	heart ventricle (left)	38
	interventricular septum	41
	fetal aorta	1
	aorta	8
	aorta sclerotic	29
30	artery	1
	coronary artery	10
	coronary artery sclerotic	4

- 95 -

	vein	4
	coronary artery smooth muscle primary cells	1
	HUVEC cells	580
5	skin	495
	adrenal gland	5185
	thyroid	228
	thyroid tumor	197
10	pancreas	1978
	pancreas liver cirrhosis	1698
	esophagus	39
	esophagus tumor	28
15	stomach	26801
	stomach tumor	393
	colon	1067
	colon tumor	62
	small intestine	15076
20	ileum	226
	ileum tumor	8
	ileum chronic inflammation	600
	rectum	2452
	salivary gland	588
25	fetal liver	218
	liver	584
	liver liver cirrhosis	6747
	liver tumor	35
	HEP G2 cells	326
30	leukocytes (peripheral blood)	51
	Jurkat (T-cells)	2
	bone marrow	34
	erythrocytes	7

- 96 -

	lymphnode	26
	thymus	153
	thrombocytes	1
	bone marrow stromal cells	12
5	bone marrow CD71+ cells	1
	bone marrow CD33+ cells	4
	bone marrow CD34+ cells	3
	bone marrow CD15+ cells	1
	cord blood CD71+ cells	1
10	spleen	37122
	spleen liver cirrhosis	102127
	skeletal muscle	568
	adipose	100
15	fetal brain	443
	brain	1652
	Alzheimer brain	2369
	cerebellum	111
20	cerebellum (right)	63
	cerebellum (left)	42
	cerebral cortex	180
	Alzheimer cerebral cortex	53
	frontal lobe	205
25	Alzheimer brain frontal lobe	146
	occipital lobe	59
	parietal lobe	38
	temporal lobe	428
	precentral gyrus	44
30	postcentral gyrus	5
	tonsilla cerebelli	83
	vermis cerebelli	154
	pons	164
	substantia nigra	452

- 97 -

	cerebral meninges	24
	cerebral peduncles	114
	corpus callosum	357
	hippocampus	133
5	thalamus	57
	dorsal root ganglia	41
	spinal cord	776
	neuroblastoma SK-N-MC cells	198
	neuroblastoma SH-SY5Y cells	8481
10	neuroblastoma IMR32 cells	12
	glial tumor H4 cells	10
	glial tumor H4 cells + APP	7
	HEK CNS	3
	HEK CNS + APP	3
15	retina	43
	fetal lung	24834
	fetal lung fibroblast IMR-90 cells	247
	lung	27554
20	lung right upper lobe	66
	lung right mid lobe	1
	lung right lower lobe	98
	lung tumor	276
	lung COPD	80
25	trachea	4096
	cervix	26
	testis	1261
	HeLa cells (cervix tumor)	867
30	placenta	512
	uterus	826
	uterus tumor	201
	ovary	98
	ovary tumor	254

- 98 -

	breast	75
	breast tumor	1448
	MDA MB 231 cells (breast tumor)	56
	mammary gland	2978
5		
	prostate	1218
	prostate BPH	11
	bladder	505
	ureter	232
10	penis	1
	corpus cavernosum	1
	fetal kidney	2419
	kidney	62001
	kidney tumor	12
15	HEK 293 cells	14

Example 3: Antisense Analysis

Knowledge of the correct, complete cDNA sequence coding for prostaglandin E2
 20 EP1 enables its use as a tool for antisense technology in the investigation of gene
 function. Oligonucleotides, cDNA or genomic fragments comprising the antisense
 strand of a polynucleotide coding for prostaglandin E2 EP1 are used either in vitro or
 in vivo to inhibit translation of the mRNA. Such technology is now well known in
 the art, and antisense molecules can be designed at various locations along the
 25 nucleotide sequences. By treatment of cells or whole test animals with such
 antisense sequences, the gene of interest is effectively turned off. Frequently, the
 function of the gene is ascertained by observing behavior at the intracellular, cellular,
 tissue or organismal level (e.g., lethality, loss of differentiated function, changes in
 morphology, etc.).

30

In addition to using sequences constructed to interrupt transcription of a particular
 open reading frame, modifications of gene expression is obtained by designing

antisense sequences to intron regions, promoter/enhancer elements, or even to trans-acting regulatory genes.

Example 4: Expression of prostaglandin E2 EP1

5

Expression of prostaglandin E2 EP1 is accomplished by subcloning the cDNAs into appropriate expression vectors and transfecting the vectors into expression hosts such as, e.g., *E. coli*. In a particular case, the vector is engineered such that it contains a promoter for β -galactosidase, upstream of the cloning site, followed by sequence
10 containing the amino-terminal Methionine and the subsequent seven residues of β -galactosidase. Immediately following these eight residues is an engineered bacteriophage promoter useful for artificial priming and transcription and for providing a number of unique endonuclease restriction sites for cloning.

15 Induction of the isolated, transfected bacterial strain with Isopropyl- β -D-thiogalactopyranoside (IPTG) using standard methods produces a fusion protein corresponding to the first seven residues of β -galactosidase, about 15 residues of "linker", and the peptide encoded within the cDNA. Since cDNA clone inserts are generated by an essentially random process, there is probability of 33% that the
20 included cDNA will lie in the correct reading frame for proper translation. If the cDNA is not in the proper reading frame, it is obtained by deletion or insertion of the appropriate number of bases using well known methods including in vitro mutagenesis, digestion with exonuclease III or mung bean nuclease, or the inclusion of an oligonucleotide linker of appropriate length.

25

The prostaglandin E2 EP1 cDNA is shuttled into other vectors known to be useful for expression of proteins in specific hosts. Oligonucleotide primers containing cloning sites as well as a segment of DNA (about 25 bases) sufficient to hybridize to stretches at both ends of the target cDNA is synthesized chemically by standard
30 methods. These primers are then used to amplify the desired gene segment by PCR. The resulting gene segment is digested with appropriate restriction enzymes under

- 100 -

standard conditions and isolated by gel electrophoresis. Alternately, similar gene segments are produced by digestion of the cDNA with appropriate restriction enzymes. Using appropriate primers, segments of coding sequence from more than one gene are ligated together and cloned in appropriate vectors. It is possible to
5 optimize expression by construction of such chimeric sequences.

Suitable expression hosts for such chimeric molecules include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells, insect cells such as Sf9 cells, yeast cells such as *Saccharomyces cerevisiae* and
10 bacterial cells such as *E. coli*. For each of these cell systems, a useful expression vector also includes an origin of replication to allow propagation in bacteria, and a selectable marker such as the β -lactamase antibiotic resistance gene to allow plasmid selection in bacteria. In addition, the vector may include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected
15 eukaryotic host cells. Vectors for use in eukaryotic expression hosts require RNA processing elements such as 3' polyadenylation sequences if such are not part of the cDNA of interest.

Additionally, the vector contains promoters or enhancers which increase gene
20 expression. Such promoters are host specific and include MMTV, SV40, and metallothionine promoters for CHO cells; trp, lac, tac and T7 promoters for bacterial hosts; and alpha factor, alcohol oxidase and PGH promoters for yeast. Transcription enhancers, such as the rous sarcoma virus enhancer, are used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through
25 standard culture methods, large quantities of recombinantly produced prostaglandin E2 EP1 are recovered from the conditioned medium and analyzed using chromatographic methods known in the art. For example, prostaglandin E2 EP1 can be cloned into the expression vector pcDNA3, as exemplified herein. This product can be used to transform, for example, HEK293 or COS by methodology standard in
30 the art. Specifically, for example, using Lipofectamine (Gibco BRL catalog no. 18324-020) mediated gene transfer.

Example 5: Isolation of Recombinant prostaglandin E2 EP1

prostaglandin E2 EP1 is expressed as a chimeric protein with one or more additional
5 polypeptide domains added to facilitate protein purification. Such purification
facilitating domains include, but are not limited to, metal chelating peptides such as
histidine-tryptophan modules that allow purification on immobilized metals [Appa
Rao, 1997] and the domain utilized in the FLAGS extension/affinity purification
system (Immunex Corp., Seattle, Washington). The inclusion of a cleavable linker
10 sequence such as Factor Xa or enterokinase (Invitrogen, Groningen, The
Netherlands) between the purification domain and the prostaglandin E2 EP1
sequence is useful to facilitate expression of prostaglandin E2 EP1.

Example 6: Testing of Chimeric GPCRs

15 Functional chimeric GPCRs are constructed by combining the extracellular receptive
sequences of a new isoform with the transmembrane and intracellular segments of a
known isoform for test purposes. This concept was demonstrated by Kobilka et al.
(1988), Science 240:1310-1316) who created a series of chimeric $\alpha 2$ - $\beta 2$ adrenergic
20 receptors (AR) by inserting progressively greater amounts of $\alpha 2$ -AR transmembrane
sequence into $\beta 2$ -AR. The binding activity of known agonists changed as the
molecule shifted from having more $\alpha 2$ than $\beta 2$ conformation, and intermediate
constructs demonstrated mixed specificity. The specificity for binding antagonists,
however, correlated with the source of the domain VII. The importance of T7G
25 domain VII for ligand recognition was also found in chimeras utilizing two yeast α -
factor receptors and is significant because the yeast receptors are classified as
miscellaneous receptors. Thus, functional role of specific domains appears to be
preserved throughout the GPCR family regardless of category.

30 In parallel fashion, internal segments or cytoplasmic domains from a particular
isoform are exchanged with the analogous domains of a known GPCRs and used to

- 102 -

identify the structural determinants responsible for coupling the receptors to trimeric G-proteins. A chimeric receptor in which domains V, VI, and the intracellular connecting loop from $\beta 2$ -AR were substituted into $\alpha 2$ -AR was shown to bind ligands with $\alpha 2$ -AR specificity, but to stimulate adenylate cyclase in the manner of $\beta 2$ -AR. This demonstrates that for adrenergic-type receptors, G-protein recognition is present in domains V and VI and their connecting loop. The opposite situation was predicted and observed for a chimera in which the V->VI loop from $\alpha 1$ -AR replaced the corresponding domain on $\beta 2$ -AR and the resulting receptor bound ligands with $\beta 2$ -AR specificity and activated G-protein-mediated phosphatidylinositol turnover in the $\alpha 1$ -AR manner. Finally, chimeras constructed from muscarinic receptors also demonstrated that V->VI loop is the major determinant for specificity of G-protein activity.

Chimeric or modified GPCRs containing substitutions in the extracellular and transmembrane regions have shown that these portions of the receptor determine ligand binding specificity. For example, two Serine residues conserved in domain V of all adrenergic and D catecholamine GPCRs are necessary for potent agonist activity. These serines are believed to form hydrogen bonds with the catechol moiety of the agonists within the GPCR binding site. Similarly, an Asp residue present in domain III of all GPCRs which bind biogenic amines is believed to form an ion pair with the ligand amine group in the GPCR binding site.

Functional, cloned GPCRs are expressed in heterologous expression systems and their biological activity assessed. One heterologous system introduces genes for a mammalian GPCR and a mammalian G-protein into yeast cells. The GPCR is shown to have appropriate ligand specificity and affinity and trigger appropriate biological activation (growth arrest and morphological changes) of the yeast cells.

An alternate procedure for testing chimeric receptors is based on the procedure utilizing the purinergic receptor (P_{2u}). Function is easily tested in cultured K562 human leukemia cells because these cells lack P_{2u} receptors. K562 cells are

- 103 -

transfected with expression vectors containing either normal or chimeric P_{2u} and loaded with fura-a, fluorescent probe for Ca⁺⁺. Activation of properly assembled and functional P_{2u} receptors with extracellular UTP or ATP mobilizes intracellular Ca⁺⁺ which reacts with fura-a and is measured spectrofluorometrically.

5

As with the GPCRs above, chimeric genes are created by combining sequences for extracellular receptive segments of any new GPCR polypeptide with the nucleotides for the transmembrane and intracellular segments of the known P_{2u} molecule. Bathing the transfected K562 cells in microwells containing appropriate ligands triggers binding and fluorescent activity defining effectors of the GPCR molecule. Once ligand and function are established, the P_{2u} system is useful for defining antagonists or inhibitors which block binding and prevent such fluorescent reactions.

10

Example 7: Production of prostaglandin E2 EP1 Specific Antibodies

15

Two approaches are utilized to raise antibodies to prostaglandin E2 EP1, and each approach is useful for generating either polyclonal or monoclonal antibodies. In one approach, denatured protein from reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits using standard protocols; about 100 µg are adequate for immunization of a mouse, while up to 1 mg might be used to immunize a rabbit. For identifying mouse hybridomas, the denatured protein is radioiodinated and used to screen potential murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg is sufficient for labeling and screening of several thousand clones.

20

25

In the second approach, the amino acid sequence of an appropriate prostaglandin E2 EP1 domain, as deduced from translation of the cDNA, is analyzed to determine regions of high antigenicity. Oligopeptides comprising appropriate hydrophilic regions are synthesized and used in suitable immunization protocols to raise antibodies. The optimal amino acid sequences for immunization are usually at the C-

30

- 104 -

terminus, the N-terminus and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the protein is in its natural conformation.

5 Typically, selected peptides, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH; Sigma, St. Louis, MO) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester, MBS. If necessary, a cysteine is introduced at the N-terminus of the peptide to permit coupling to KLH.
10 Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin, reacting with antisera, washing and reacting with labeled (radioactive or fluorescent), affinity purified, specific goat anti-rabbit IgG.

15

Hybridomas are prepared and screened using standard techniques. Hybridomas of interest are detected by screening with labeled prostaglandin E2 EP1 to identify those fusions producing the monoclonal antibody with the desired specificity. In a typical protocol, wells of plates (FAST; Becton-Dickinson, Palo Alto, CA) are coated during
20 incubation with affinity purified, specific rabbit anti-mouse (or suitable antispecies 1 g) antibodies at 10 mg/ml. The coated wells are blocked with 1% bovine serum albumin, (BSA), washed and incubated with supernatants from hybridomas. After washing the wells are incubated with labeled prostaglandin E2 EP1 at 1 mg/ml. Supernatants with specific antibodies bind more labeled prostaglandin E2 EP1 than is
25 detectable in the background. Then clones producing specific antibodies are expanded and subjected to two cycles of cloning at limiting dilution. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from mouse ascitic fluid by affinity chromatography on Protein A. Monoclonal antibodies with affinities of at least

30

10^8 M^{-1} , preferably 10^9 to 10^{10} M^{-1} or stronger, are typically made by standard procedures.

Example 8: Diagnostic Test Using prostaglandin E2 EP1 Specific Antibodies

5

Particular prostaglandin E2 EP1 antibodies are useful for investigating signal transduction and the diagnosis of infectious or hereditary conditions which are characterized by differences in the amount or distribution of prostaglandin E2 EP1 or downstream products of an active signaling cascade.

10

Diagnostic tests for prostaglandin E2 EP1 include methods utilizing antibody and a label to detect prostaglandin E2 EP1 in human body fluids, membranes, cells, tissues or extracts of such. The polypeptides and antibodies of the present invention are used with or without modification. Frequently, the polypeptides and antibodies are labeled by joining them, either covalently or noncovalently, with a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and have been reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, chromogenic agents, magnetic particles and the like.

20

A variety of protocols for measuring soluble or membrane-bound prostaglandin E2 EP1, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on prostaglandin E2 EP1 is preferred, but a competitive binding assay may be employed.

25

- 106 -

Example 9: Purification of Native prostaglandin E2 EP1 Using Specific Antibodies

Native or recombinant prostaglandin E2 EP1 is purified by immunoaffinity chromatography using antibodies specific for prostaglandin E2 EP1. In general, an immunoaffinity column is constructed by covalently coupling the anti-TRH antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such immunoaffinity columns are utilized in the purification of prostaglandin E2 EP1 by preparing a fraction from cells containing prostaglandin E2 EP1 in a soluble form. This preparation is derived by solubilization of whole cells or of a subcellular fraction obtained via differential centrifugation (with or without addition of detergent) or by other methods well known in the art. Alternatively, soluble prostaglandin E2 EP1 containing a signal sequence is secreted in useful quantity into the medium in which the cells are grown.

A soluble prostaglandin E2 EP1-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of prostaglandin E2 EP1 (e.g., high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt

antibody/protein binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and prostaglandin E2 EP1 is collected.

Example 10: Drug Screening

5

This invention is particularly useful for screening therapeutic compounds by using prostaglandin E2 EP1 or binding fragments thereof in any of a variety of drug screening techniques. As prostaglandin E2 EP1 is a G protein coupled receptor any of the methods commonly used in the art may potentially be used to identify
10 prostaglandin E2 EP1 ligands. For example, the activity of a G protein coupled receptor such as prostaglandin E2 EP1 can be measured using any of a variety of appropriate functional assays in which activation of the receptor results in an observable change in the level of some second messenger system, such as adenylate cyclase, guanylylcyclase, calcium mobilization, or inositol phospholipid hydrolysis.
15 Alternatively, the polypeptide or fragment employed in such a test is either free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding
20 assays. Such cells, either in viable or fixed form, are used for standard binding assays.

Measured, for example, is the formation of complexes between prostaglandin E2 EP1 and the agent being tested. Alternatively, one examines the diminution in complex
25 formation between prostaglandin E2 EP1 and a ligand caused by the agent being tested.

Thus, the present invention provides methods of screening for drug candidates, drugs, or any other agents which affect signal transduction. These methods, well known in
30 the art, comprise contacting such an agent with prostaglandin E2 EP1 polypeptide or a fragment thereof and assaying (i) for the presence of a complex between the agent

- 108 -

and prostaglandin E2 EP1 polypeptide or fragment, or (ii) for the presence of a complex between prostaglandin E2 EP1 polypeptide or fragment and the cell. In such competitive binding assays, the prostaglandin E2 EP1 polypeptide or fragment is typically labeled. After suitable incubation, free prostaglandin E2 EP1 polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to prostaglandin E2 EP1 or to interfere with the prostaglandin E2 EP1-agent complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to prostaglandin E2 EP1 polypeptides. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with prostaglandin E2 EP1 polypeptide and washed. Bound prostaglandin E2 EP1 polypeptide is then detected by methods well known in the art. Purified prostaglandin E2 EP1 are also coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies are used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding prostaglandin E2 EP1 specifically compete with a test compound for binding to prostaglandin E2 EP1 polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic determinants with prostaglandin E2 EP1.

Example 11: Rational Drug Design

The goal of rational drug design is to produce structural analogs of biologically active polypeptides of interest or of small molecules with which they interact, agonists, antagonists, or inhibitors. Any of these examples are used to fashion drugs

which are more active or stable forms of the polypeptide or which enhance or interfere with the function of a polypeptide in vivo.

5 In one approach, the three-dimensional structure of a protein of interest, or of a protein-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide is gained by modeling based on the structure of
10 homologous proteins. In both cases, relevant structural information is used to design efficient inhibitors. Useful examples of rational drug design include molecules which have improved activity or stability or which act as inhibitors, agonists, or antagonists of native peptides.

15 It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design is based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a
20 mirror image, the binding site of the anti-ids is expected to be an analog of the original receptor. The anti-id is then used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides then act as the pharmacore.

25 By virtue of the present invention, sufficient amount of polypeptide are made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the prostaglandin E2 EP1 amino acid sequence provided herein provides guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

Example 12: Identification of Other Members of the Signal Transduction Complex

The inventive purified prostaglandin E2 EP1 is a research tool for identification, characterization and purification of interacting G or other signal transduction pathway proteins. Radioactive labels are incorporated into a selected prostaglandin E2 EP1 domain by various methods known in the art and used in vitro to capture interacting molecules. A preferred method involves labeling the primary amino groups in prostaglandin E2 EP1 with ^{125}I Bolton-Hunter reagent. This reagent has been used to label various molecules without concomitant loss of biological activity.

Labeled prostaglandin E2 EP1 is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, membrane-bound prostaglandin E2 EP1 is covalently coupled to a chromatography column. Cell-free extract derived from synovial cells or putative target cells is passed over the column, and molecules with appropriate affinity bind to prostaglandin E2 EP1. prostaglandin E2 EP1-complex is recovered from the column, and the prostaglandin E2 EP1-binding ligand disassociated and subjected to N-terminal protein sequencing. The amino acid sequence information is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

In an alternate method, antibodies are raised against prostaglandin E2 EP1, specifically monoclonal antibodies. The monoclonal antibodies are screened to identify those which inhibit the binding of labeled prostaglandin E2 EP1. These monoclonal antibodies are then used therapeutically.

Example 13: Use and Administration of Antibodies, Inhibitors, or Antagonists

Antibodies, inhibitors, or antagonists of prostaglandin E2 EP1 or other treatments and compounds that are limiters of signal transduction (LSTs), provide different

effects when administered therapeutically. LSTs are formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium preferably at a pH of about 5 to 8, more preferably 6 to 8, although pH may vary according to the characteristics of the antibody, inhibitor, or antagonist being formulated and the condition to be treated. Characteristics of LSTs include solubility of the molecule, its half-life and antigenicity/immunogenicity. These and other characteristics aid in defining an effective carrier. Native human proteins are preferred as LSTs, but organic or synthetic molecules resulting from drug screens are equally effective in particular situations.

LSTs are delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes. The particular formulation, exact dosage, and route of administration is determined by the attending physician and varies according to each specific situation.

Such determinations are made by considering multiple variables such as the condition to be treated, the LST to be administered, and the pharmacokinetic profile of a particular LST. Additional factors which are taken into account include severity of the disease state, patient's age, weight, gender and diet, time and frequency of LST administration, possible combination with other drugs, reaction sensitivities, and tolerance/response to therapy. Long acting LST formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular LST.

Normal dosage amounts vary from 0.1 to 10^5 μ g, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art employ different formulations for

- 112 -

different LSTs. Administration to cells such as nerve cells necessitates delivery in a manner different from that to other cells such as vascular endothelial cells.

5 It is contemplated that abnormal signal transduction, trauma, or diseases which trigger prostaglandin E2 EP1 activity are treatable with LSTs. These conditions or diseases are specifically diagnosed by the tests discussed above, and such testing should be performed in suspected cases of viral, bacterial or fungal infections, allergic responses, mechanical injury associated with trauma, hereditary diseases, lymphoma or carcinoma, or other conditions which activate the genes of lymphoid or
10 neuronal tissues.

Example 14: Production of Non-human Transgenic Animals

15 Animal model systems which elucidate the physiological and behavioral roles of the prostaglandin E2 EP1 are produced by creating nonhuman transgenic animals in which the activity of the prostaglandin E2 EP1 is either increased or decreased, or the amino acid sequence of the expressed prostaglandin E2 EP1 is altered, by a variety of techniques. Examples of these techniques include, but are not limited to: 1) Insertion of normal or mutant versions of DNA encoding a prostaglandin E2 EP1, by
20 microinjection, electroporation, retroviral transfection or other means well known to those skilled in the art, into appropriately fertilized embryos in order to produce a transgenic animal or 2) homologous recombination of mutant or normal, human or animal versions of these genes with the native gene locus in transgenic animals to alter the regulation of expression or the structure of these prostaglandin E2 EP1
25 sequences. The technique of homologous recombination is well known in the art. It replaces the native gene with the inserted gene and hence is useful for producing an animal that cannot express native prostaglandin E2 EP1s but does express, for example, an inserted mutant prostaglandin E2 EP1, which has replaced the native prostaglandin E2 EP1 in the animal's genome by recombination, resulting in
30 underexpression of the transporter. Microinjection adds genes to the genome, but does not remove them, and the technique is useful for producing an animal which

- 113 -

expresses its own and added prostaglandin E2 EP1, resulting in overexpression of the prostaglandin E2 EP1.

One means available for producing a transgenic animal, with a mouse as an example,
5 is as follows: Female mice are mated, and the resulting fertilized eggs are dissected
out of their oviducts. The eggs are stored in an appropriate medium such as
cesiumchloride M2 medium. DNA or cDNA encoding prostaglandin E2 EP1 is
purified from a vector by methods well known to the one skilled in the art. Inducible
10 promoters may be fused with the coding region of the DNA to provide an
experimental means to regulate expression of the transgene. Alternatively or in
addition, tissue specific regulatory elements may be fused with the coding region to
permit tissue-specific expression of the transgene. The DNA, in an appropriately
buffered solution, is put into a microinjection needle (which may be made from
15 capillary tubing using a piper puller) and the egg to be injected is put in a depression
slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is
injected. The injected egg is then transferred into the oviduct of a pseudopregnant
mouse which is a mouse stimulated by the appropriate hormones in order to maintain
false pregnancy, where it proceeds to the uterus, implants, and develops to term. As
20 noted above, microinjection is not the only method for inserting DNA into the egg
but is used here only for exemplary purposes.

References

U.S. 4,522,811
25 U.S. 5,283,317
U.S. 5,565,332
U.S. 5,985,597
U.S. 6,440,680
WO 84/03564
30 WO 92/01810
WO 93/03151

- WO 94/13804
WO 01/04297
WO 01/77172
WO 02/061087
5 WO 02/081745
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ;
Nucleic Acids Res 1997 Sep 1; 25(17): 3389-402
Appa Rao et al., 1997, Protein Expr Purif Nov, 11(2): 201-8
Barnes, 2000, Chest, 117:10S14S
- 10 Botstein et al., 1980 , Am J Hum Genet. 32: 314-31
Colbere-Garapin *et al.*, 1981, *J. Mol. Biol.* 150, 1-14
Coleman et al., Pharm. Rev. 46: 205-229, 1994.
Engelhard *et al.*, 1994, *Proc. Nat. Acad. Sci.* 91, 3224-3227
Funk et al., J Biol Chem. 1993 Dec 15;268(35):26767-72.
- 15 Gergen and Weiss, 1992, Am Rev Respir Dis 146:823-824
Gibson et al., 1996, Genome Research 6: 995-1001
Haseloff *et al.*, 1988, *Nature* 334, 585-591
Heid et al., 1996, Genome Research 6: 986-994
Holland et al., 1991, PNAS 88: 7276-7280
- 20 Iwabuchi *et al.*, 1993, *Oncogene* 8, 1693-1696
Jeffreys et al., 1985, *Nature* 316: 76-9
Johnson *et al.*, 1989, *Endoc. Rev.* 10, 317-331
Kellogg et al., 1990, Anal. Biochem. 189:202-208
Lam, 1997, Anticancer Drug Res. 12(3):145-67
- 25 Lefkowitz, 1991 , *Nature* 351, 353-354
Livak et al., 1995 , PCR Methods and Applications 357-362
Logan, Shenk, 1984, *Proc. Natl. Acad. Sci.* 81, 3655-3659
Lowy *et al.*, 1980, *Cell* 22, 817-23
Maddox *et al.*, 1983, *J. Exp. Med.* 158, 1211-1216
- 30 McConnell *et al.*, 1992, *Science* 257, 1906-1912
Nicholls *et al.*, 1993, *J. Immunol. Meth.* 165, 81-91

- Piatak et al., 1993, *BioTechniques* 14:70-81
- Piatak et al., 1993, *Science* 259:1749-1754
- Porath *et al.*, 1992, *Prot. Exp. Purif.* 3, 263-281
- Roberge *et al.*, 1995, *Science* 269, 202-204
- 5 Sales et al., *Clin. Endocr. Metab.* 86: 2243-2249, 2001.
- Sjolander, Urbaniczky, 1991, *Anal. Chem.* 63, 2338-2345
- Szabo *et al.*, 1995, *Curr. Opin. Struct. Biol.* 5, 699-705
- Thomas, 1980, *Proc. Nat. Acad. Sci.*, 77:5201-5205
- Uhlmann *et al.*, 1987, *Tetrahedron. Lett.* 215, 3539-3542
- 10 Weber et al., 1990, *Genomics* 7: 524-30
- Wigler *et al.*, 1977, *Cell* 11, 223-32
- Wigler *et al.*, 1980, *Proc. Natl. Acad. Sci.* 77, 3567-70

Claims

1. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of
 - i) contacting a test compound with a prostaglandin E2 EP1 polypeptide,
 - ii) detect binding of said test compound to said prostaglandin E2 EP1 polypeptide.
2. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of
 - i) determining the activity of a prostaglandin E2 EP1 polypeptide at a certain concentration of a test compound or in the absence of said test compound,
 - ii) determining the activity of said polypeptide at a different concentration of said test compound.
3. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of

- 117 -

- i) determining the activity of a prostaglandin E2 EP1 polypeptide at a certain concentration of a test compound,
 - 5 ii) determining the activity of a prostaglandin E2 EP1 polypeptide at the presence of a compound known to be a regulator of a prostaglandin E2 EP1 polypeptide.
- 10 4. The method of any of claims 1 to 3, wherein the step of contacting is in or at the surface of a cell.
5. The method of any of claims 1 to 3, wherein the cell is in vitro.
- 15 6. The method of any of claims 1 to 3, wherein the step of contacting is in a cell-free system.
7. The method of any of claims 1 to 3, wherein the polypeptide is coupled to a detectable label.
- 20 8. The method of any of claims 1 to 3, wherein the compound is coupled to a detectable label.
9. The method of any of claims 1 to 3, wherein the test compound displaces a ligand which is first bound to the polypeptide.
- 25 10. The method of any of claims 1 to 3, wherein the polypeptide is attached to a solid support.
- 30 11. The method of any of claims 1 to 3, wherein the compound is attached to a solid support.

- 118 -

12. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of
- 5
- i) contacting a test compound with a prostaglandin E2 EP1 polynucleotide,
- 10 ii) detect binding of said test compound to said prostaglandin E2 EP1 polynucleotide.
13. The method of claim 12 wherein the nucleic acid molecule is RNA.
- 15 14. The method of claim 12 wherein the contacting step is in or at the surface of a cell.
15. The method of claim 12 wherein the contacting step is in a cell-free system.
- 20 16. The method of claim 12 wherein polynucleotide is coupled to a detectable label.
17. The method of claim 12 wherein the test compound is coupled to a detectable label.
- 25
18. A method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of
- 30

- 119 -

- i) determining the amount of a prostaglandin E2 EP1 polynucleotide in a sample taken from said mammal,
- ii) determining the amount of prostaglandin E2 EP1 polynucleotide in healthy and/or diseased mammals.
19. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising a therapeutic agent which binds to a prostaglandin E2 EP1 polypeptide.
20. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising a therapeutic agent which regulates the activity of a prostaglandin E2 EP1 polypeptide.
21. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising a therapeutic agent which regulates the activity of a prostaglandin E2 EP1 polypeptide, wherein said therapeutic agent is
- i) a small molecule,
- ii) an RNA molecule,
- iii) an antisense oligonucleotide,
- iv) a polypeptide,
- v) an antibody, or

- 120 -

vi) a ribozyme.

22. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising a prostaglandin E2 EP1 polynucleotide.
23. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising a prostaglandin E2 EP1 polypeptide.
24. Use of regulators of a prostaglandin E2 EP1 for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal.
25. Method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal comprising the steps of
- i) identifying a regulator of prostaglandin E2 EP1,
 - ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological

- 121 -

diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases in a mammal; and

iii) combining of said regulator with an acceptable pharmaceutical carrier.

5

26. Use of a regulator of prostaglandin E2 EP1 for the regulation of prostaglandin E2 EP1 activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases.

10

- 1/2 -

Fig. 1**SEQ ID NO: 1**

GGGGGCGGCAGGGCTGAGCGGCCGGTGATGGGGACCCACATCCCAGG
CAGTGCCGGCACCCCTGGCGCCTGACATGAGCCCTTGCGGGCCCCTCA
ACCTGAGCCTGGCGGGCGAGGCGACCACATGCGCGGCGCCCTGGGTCC
CCAACACGTGCGGCCGTGCCGCCGTGCGGGCGCTTCGCCCCGCGCTGCCCA
TCTTCTCCATGACGCTGGGCGCCGTGTCCAACCTGCTGGCGCTGGCGC
TGCTGGCGCAGGCCGCGGGCCGCTGCGACGCCGCCGCTCGGCCACCA
CCTTCCTGCTGTTTCGTGGCCAGCCTGCTGGCCACCGACCTGGCGGGCC
ACGTGATCCCGGGCGCGCTGGTGCTGCGTCTGTACACTGCGGGGCGCG
CTCCGGCCGGCGGGGGCCTGCCACTTCCTGGGCGGCTGCATGGTCTTCT
TCGGCCTGTGCCCCGCTGCTGCTGGGCTGTGGCATGGCCGTGGAGCGCT
GCGTGGGCGTCACGCGGCCGCTGCTCCACGCCGCGCGGGTCTCGGTGCG
CCCGCGCGCGCCTGGCGCTGGCCGCGGTGGCCGCGGTGGCCTTGGCCG
TGGCGCTGCTGCCGCTGGCGCGCGTGGGCCGCTATGAGCTGCAGTACC
CGGGCACGTGGTGCTTCATCGGCCTGGGTCCCCCGGGCGGCTGGCGCC
AGGCACTGCTTGCTGGCCTCTTCGCCAGCCTCGGCCTGGTTCGCGCTCC
TCGCCGCGCTGGTGTGCAACACGCTCAGCGGCCTGGCCCTGCATCGCG
CCCGCTGGCGACGCCGCTCCCGACGGCCTCCCCCGGCCTCAGGCCCCG
ACAGCCGGCGTCGCTGGGGGGCGCACGGACCCCGCTCGGCCTCCGCCT
CGTCCGCCTCGTCCATCGCTTCGGCCTCCACCTTCTTTGGCGGCTCTC
GGAGCAGCGGCTCGGCACGCAGAGCTCGCGCCACGACGTGGAGATGG
TGGGCCAGCTTGTCGGTATCATGGTGGTGTGTCGTGCATCTGCTGGAGCC
CAATGCTGGTGTGTTGGTGGCGCTGGCCGTGCGCGGCTGGAGCTCTACCT
CCCTGCAGCGGCCACTGTTCTCGGCCGTGCGCCTTGCTCCTGGAACC
AGATCCTGGACCCCTTGGGTGTACATCCTACTGCGCCAGGCCGTGCTGC
GCCAACTGCTTCGCCTCTTGCCCCGAGGGCCGGAGCCAAGGGCGGCC
CCGCGGGGCTGGGCCTAACACCGAGCGCCTGGGAGGCCAGCTCGCTGC
GCAGCTCCCGGCACAGCGGCCTCAGCCACTTCTAAGCACAACCAGAGG
CCCAACGACTAAGCCAGCCCACCCTGGGCTGGGCCAGGTGCGCGGCG
CAGAGCCTTTGGGAATAAAAAGCCATTCTGCG

- 2/2 -

Fig. 2**SEQ ID NO: 2**

MSPCGPLNLSLAGEATTCAAPWVPNTSAVPPSGASPALPIFSMTLGAV
SNLLALALLAQAAGRLRRRRSATTFLLFVASLLATDLAGHVIPGALVL
RLYTAGRAPAGGACHFLGGCMVFFGLCPLLLGCGMAVERCVGVTRPLL
HAARVSVARARLALAAVAVALAVALLPLARVGRYELQYPGTWCFIGL
GPPGGWRQALLAGLFASLGLVALLAALVCNTLSGLALHRARWRRRSRR
PPPASGPDSSRRRWGAHGPRASASSASSIASASTFFGGSRSSGSARRA
RAHDVEMVGQLVGIMVVSCICWSPMLVLVALAVGGWSSTSLQRPLFLA
VRLASWNQILDPWVYILLRQAVLRQLLRLLPPRAGAKGGPAGLGLTPS
AWEASSLRSSRHSGLSHF

Fig. 3**SEQ ID NO: 3**

5'-ggccagcttgctcggtatc-3'

Fig. 4**SEQ ID NO: 4**

5'-gccaccaacaccagcatt-3'

Fig. 5**SEQ ID NO: 5**

5'-tggtgtcgtgcatctgctggag-3'

- 1 -

SEQUENCE LISTING

<110> Bayer AG, BHC

<120> Diagnostics and Therapeutics for Diseases Associated with G-Protein Coupled Receptor Prostaglandin E2 EP1 (Prostaglandin E2 EP1)

<130> Le A 36 602

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 1376

<212> DNA

<213> Homo sapiens

<400> 1

```

gggggaggca gggctgagcg gccggtgatg gggacccac atcccaggca gtgccggcac    60
ccctggcgcc tgacatgagc ccttgccggc ccctcaacct gagcctggcg ggcgaggcga    120
ccacatgcgc ggccgctggg gtccccaaca cgctcgccgt gccgcccgtc ggcgcttcgc    180
ccgcgctgcc catcttctcc atgacgttgg gcgcgctgtc caacctgctg gcgctggcgc    240
tgctggcgca ggccgcgggc cgcctgacac gccgcgctc ggccaccacc ttcctgctgt    300
tcgtggccag cctgctggcc accgacctgg cgggccacgt gatcccgggc gcgctggtgc    360
tgcgtctgta cactgcgggg cgcgctccgg ccggcggggc ctgccacttc ctgggcggct    420
gcatggtctt ctccggcctg tgcccgtgct tgctgggctg tggcatggcc gtggagcgct    480
gcgtggcgct cagcgggcgc ctgctccacg ccgcgcgggt ctcggtcgcc cgcgcgcgcc    540
tggcgctggc cgcggtggcc gcggtggcct tggcgctggc gctgctgccc ctggcgcgcg    600
tgggccccta tgagctgcag taccggggca cgtggtgctt catcggcctg ggtcccccg    660
gcggtggcg ccaggcaact cttgctggcc tcttcgccag cctcggcctg gtcgcgctcc    720
tcgcccgcgt ggtgtgcaac acgctcagcg gcctggccct gcatcgcgcc cgctggcgac    780
gccgctcccg accgctccc ccggcctcag gcccgcagac ccggcgctgc tggggggcgc    840
accgaccccg ctgcgctccc gcctcgctcc cctcgctcat cgcttcggcc tccaccttct    900
ttggcggtct tcggagcagc ggctcggcac gcagagctcg cggccacgac gtggagatgg    960
tgggccaact tgtcggtatc atggtggtgt cgtgcatctg ctggagccca atgctggtgt   1020
tggtggcgct ggcgctggc ggctggagct ctacctccct gcagcgccca ctgttctctg   1080
ccgtgcgcct tgctcctgg aaccagatcc tggacccttg ggtgtacatc ctactcgccc   1140
aggcggtgct ggcgcaactg cttcgctctt tgcccccgag ggccggagcc aaggggcgcc   1200
ccgcgggggt gggcctaaca ccgagcgctt gggaggccag ctgctgctgc agtcccggc   1260
acagcggcct cagccaattc taagcacaac cagaggccca acgactaagc cagccacccc   1320
tgggctgggc ccagtgcgcc ggccgagagc ctttgggaat aaaaagccat tctgctg   1376

```

<210> 2

<211> 402

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Ser Pro Cys Gly Pro Leu Asn Leu Ser Leu Ala Gly Glu Ala Thr
1          5          10          15
Thr Cys Ala Ala Pro Trp Val Pro Asn Thr Ser Ala Val Pro Pro Ser
20        25        30
Gly Ala Ser Pro Ala Leu Pro Ile Phe Ser Met Thr Leu Gly Ala Val
35        40        45
Ser Asn Leu Leu Ala Leu Ala Leu Leu Ala Gln Ala Ala Gly Arg Leu
50        55        60
Arg Arg Arg Arg Ser Ala Thr Thr Phe Leu Leu Phe Val Ala Ser Leu
65        70        75        80
Leu Ala Thr Asp Leu Ala Gly His Val Ile Pro Gly Ala Leu Val Leu
85        90        95
Arg Leu Tyr Thr Ala Gly Arg Ala Pro Ala Gly Gly Ala Cys His Phe
100       105       110
Leu Gly Gly Cys Met Val Phe Phe Gly Leu Cys Pro Leu Leu Leu Gly
115       120       125
Cys Gly Met Ala Val Glu Arg Cys Val Gly Val Thr Arg Pro Leu Leu
130       135       140

```

- 2 -

His Ala Ala Arg Val Ser Val Ala Arg Ala Arg Leu Ala Leu Ala Ala
 145 150 155 160
 Val Ala Ala Val Ala Leu Ala Val Ala Leu Leu Pro Leu Ala Arg Val
 165 170 175
 Gly Arg Tyr Glu Leu Gln Tyr Pro Gly Thr Trp Cys Phe Ile Gly Leu
 180 185 190
 Gly Pro Pro Gly Gly Trp Arg Gln Ala Leu Leu Ala Gly Leu Phe Ala
 195 200 205
 Ser Leu Gly Leu Val Ala Leu Leu Ala Ala Leu Val Cys Asn Thr Leu
 210 215 220
 Ser Gly Leu Ala Leu His Arg Ala Arg Trp Arg Arg Arg Ser Arg Arg
 225 230 235 240
 Pro Pro Pro Ala Ser Gly Pro Asp Ser Arg Arg Arg Trp Gly Ala His
 245 250 255
 Gly Pro Arg Ser Ala Ser Ala Ser Ser Ala Ser Ser Ile Ala Ser Ala
 260 265 270
 Ser Thr Phe Gly Gly Ser Arg Ser Ser Gly Ser Ala Arg Arg Ala
 275 280 285
 Arg Ala His Asp Val Glu Met Val Gly Gln Leu Val Gly Ile Met Val
 290 295 300
 Val Ser Cys Ile Cys Trp Ser Pro Met Leu Val Leu Val Ala Leu Ala
 305 310 315 320
 Val Gly Gly Trp Ser Ser Thr Ser Leu Gln Arg Pro Leu Phe Leu Ala
 325 330 335
 Val Arg Leu Ala Ser Trp Asn Gln Ile Leu Asp Pro Trp Val Tyr Ile
 340 345 350
 Leu Leu Arg Gln Ala Val Leu Arg Gln Leu Leu Arg Leu Leu Pro Pro
 355 360 365
 Arg Ala Gly Ala Lys Gly Gly Pro Ala Gly Leu Gly Leu Thr Pro Ser
 370 375 380
 Ala Trp Glu Ala Ser Ser Leu Arg Ser Ser Arg His Ser Gly Leu Ser
 385 390 395 400
 His Phe

<210> 3
 <211> 18
 <212> DNA
 <213> artificial sequence

<220>
 <223> forward primer

<400> 3
 ggccagcttg tcggtatc

18

<210> 4
 <211> 18
 <212> DNA
 <213> artificial sequence

<220>
 <223> reverse primer

<400> 4
 gccaccaaca ccagcatt

18

<210> 5
 <211> 22
 <212> DNA
 <213> artificial sequence

<220>
 <223> probe

<400> 5
 tgggtgctgtg catctgctgg ag

22

INTERNATIONAL SEARCH REPORT

PCT/EP2004/001199

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 G01N33/88 C12Q1/68		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 7 G01N C12Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, SEQUENCE SEARCH		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 440 680 B1 (FORD-HUTCHINSON ANTHONY ET AL) 27 August 2002 (2002-08-27) cited in the application column 9, line 50-62; claims 1-26 ---	1-17
X	WO 94/28125 A (FORD HUTCHINSON ANTHONY ;MERCK FROSST CANADA INC (CA); GRYGORCZYK) 8 December 1994 (1994-12-08) page 16, last paragraph -page 17, paragraph 1; claim 8 ---	1-17
X	WO 00/29614 A (EURONA MEDICAL AB) 25 May 2000 (2000-05-25) page 8; claim 27 claims 1-6 --- -/--	1-18
☒ Further documents are listed in the continuation of box C. ☒ Patent family members are listed in annex.		
° Special categories of cited documents :		
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search 17 May 2004	Date of mailing of the international search report 09/06/2004	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Cuendet, P	

INTERNATIONAL SEARCH REPORT

PCT/EP2004/001199

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/077226 A (ONO PHARMACEUTICAL CO ;TAJIMA HISAO (JP)) 3 October 2002 (2002-10-03) abstract -----	1-17, 22, 23
X	EP 1 130 122 A (ASTRAZENECA AB) 5 September 2001 (2001-09-05) paragraph '0005!; claims 7,13 -----	18-26
X	WO 02/15902 A (MERCK FROSST CANADA INC ;NANTEL FRANCOIS J (CA); TURNER MERVYN (CA) 28 February 2002 (2002-02-28) claims 17,18 -----	19-21, 24-26

INTERNATIONAL SEARCH REPORT

PCT/EP2004/001199

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT – Diagnostic method practised on the human or animal body,
cf. claim 18 ii)
2. ☒ Claims Nos.: —
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Present claims 19-21,24-26: relate to an agent/regulator defined by reference to a desirable characteristic or property, namely "which binds/regulates...". These claims cover all agents/regulators having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such agents/regulators. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the agents/regulators by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, only a partial search has been carried out for these claims 19-21,24-26; i.e. the agents/regulators disclosed in EP-A-1130122 and in W00215902 are cited against these claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

PCT/EP2004/001199

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6440680	B1	27-08-2002	US 6031079 A	29-02-2000
			US 5985597 A	16-11-1999
			AT 157398 T	15-09-1997
			AU 6839994 A	20-12-1994
			CA 2163755 A1	08-12-1994
			CA 2329473 A1	08-12-1994
			WO 9428125 A2	08-12-1994
			DE 69405230 D1	02-10-1997
			DE 69405230 T2	12-03-1998
			DK 700437 T3	29-09-1997
			EP 0700437 A1	13-03-1996
			ES 2106544 T3	01-11-1997
			GR 3025402 T3	27-02-1998
			JP 9505202 T	27-05-1997
			JP 3090472 B2	18-09-2000
			MX 9403899 A1	31-01-1995
WO 9428125	A	08-12-1994	US 5985597 A	16-11-1999
			AT 157398 T	15-09-1997
			AU 6839994 A	20-12-1994
			CA 2163755 A1	08-12-1994
			CA 2329473 A1	08-12-1994
			WO 9428125 A2	08-12-1994
			DE 69405230 D1	02-10-1997
			DE 69405230 T2	12-03-1998
			DK 700437 T3	29-09-1997
			EP 0700437 A1	13-03-1996
			ES 2106544 T3	01-11-1997
			GR 3025402 T3	27-02-1998
			JP 9505202 T	27-05-1997
			JP 3090472 B2	18-09-2000
			MX 9403899 A1	31-01-1995
			US 6031079 A	29-02-2000
			US 6440680 B1	27-08-2002
WO 0029614	A	25-05-2000	WO 0029614 A1	25-05-2000
			AU 9756898 A	05-06-2000
WO 02077226	A	03-10-2002	WO 02077226 A1	03-10-2002
EP 1130122	A	05-09-2001	EP 1130122 A2	05-09-2001
			JP 2001286288 A	16-10-2001
			US 2002076702 A1	20-06-2002
WO 0215902	A	28-02-2002	AU 8655701 A	04-03-2002
			WO 0215902 A1	28-02-2002
			US 2002137746 A1	26-09-2002